Assess the effectiveness of psycho education module on knowledge regarding extra pyramidal symptoms among caregivers of patients on antipsychotic drugs attending outpatient department at Institute of Mental Health, Chennai by Bellarmin-fernando Prudensia,
1 
 
DISSERTATION 
ON 
 
“ASSESS THE EFFECTIVENESS OF PSYCHO EDUCATION 
MODULE ON KNOWLEDGE REGARDING EXTRA PYRAMIDAL 
SYMPTOMS AMONG CAREGIVERS OF PATIENTS ON 
ANTIPSYCHOTIC DRUGS ATTENDING OUTPATIENT 
DEPARTMENT AT IMH, CHENNAI” 
 
M.Sc (NURSING) DEGREE EXAMINATION 
BRANCH – V MENTAL HEALTH NURSING 
 
 
COLLEGE OF NURSING 
MADRAS MEDICAL COLLEGE, CHENNAI -03. 
 
 
 
 
 
 
 
 
 
 
A dissertation submitted to 
THE TAMILNADU DR.M.G.R MEDICAL UNIVERSITY, 
CHENNAI-600 032. 
In partial fulfillment of the requirement for the award of the degree of 
MASTER OF SCIENCE IN NURSING 
OCTOBER 2018 
 
2 
 
ASSESS THE EFFECTIVENESS OF PSYCHO EDUCATION MODULE 
ON KNOWLEDGE REGARDING EXTRA PYRAMIDAL SYMPTOMS 
AMONG CAREGIVERS OF PATIENTS ON ANTIPSYCHOTIC DRUGS 
ATTENDING OUTPATIENT DEPARTMENT AT IMH, CHENNAI. 
 
 
 
Examination   : M.Sc (N) Degree Examination 
Examination Month and Year : _________________________ 
Branch and course   : V- MENTAL HEALTH NURSING 
Register No    :  
Institution    : MADRAS MEDICAL COLLEGE, 
       COLLEGE OF NURSING. 
 
 
 
Sd: ____________________            Sd: ___________________ 
Internal Examiner     External Examiner 
Date: ___________________   Date: __________________ 
 
 
 
THE TAMILNADU DR.M.G.R MEDICAL UNIVERSITY, 
CHENNAI-600 032. 
 
 
 
 
3 
 
 
CERTIFICATE 
 
                     This is to certify that the dissertation titled “ASSESS THE 
EFFECTIVENESS OF PSYCHO EDUCATION MODULE ON 
KNOWLEDGE REGARDING EXTRA PYRAMIDAL SYMPTOMS 
AMONG CAREGIVERS OF PATIENTS ON ANTIPSYCHOTIC DRUGS 
ATTENDING OUTPATIENT DEPARTMENT AT IMH, CHENNAI” is a 
bonafide work done by  Mrs. Bellarmin-fernando  Prudensia,  M.Sc Nursing 
II year Student, College of Nursing, Madras Medical College, Chennai-3 
submitted to The Tamil Nadu Dr. M.G.R Medical University, Chennai, in 
partial fulfillment of the requirement for the award of degree of MASTER OF 
SCIENCE IN NURSING ,BRANCH-V, MENTAL HEALTH NURSING, 
under our guidance and supervision during the academic year 2016 -2018.  
 
 
 
 
Mrs.A.Thahira begum, M.Sc (N), M.B.A, M.Phil.           Dr.R.Jayanthi, M.D., F.R.C.P.,(Glasg) 
Principal,                                                           Dean, 
College of Nursing,                                             Madras Medical College, 
Madras Medical College,                                                       Chennai-03.  
Chennai-03.  
 
  
4 
 
ASSESS THE EFFECTIVENESS OF PSYCHO EDUCATION 
MODULE ON KNOWLEDGE REGARDING EXTRA 
PYRAMIDAL SYMPTOMS AMONG CAREGIVERS OF 
PATIENTS ON ANTIPSYCHOTIC DRUGS ATTENDING 
OUTPATIENT DEPARTMENT AT IMH, CHENNAI. 
 
 
Approved by the dissertation committee on      11.07.2017 
 
RESEARCH GUIDE                                         
Mrs. A.Thahira Begum, M.Sc (N)., M.B.A.,M.Phil.,____________________ 
Principal 
College of Nursing, 
Madras Medical College, 
Chennai-03. 
CLINICAL SPECIALTY GUIDE 
Mr. M. Nithyanantham, M.Sc (N)., (Ph.D).,             _______________________ 
Reader Head of the department, 
Department of Psychiatric nursing, 
Madras Medical College, 
Chennai-03. 
MEDICAL GUIDE 
DR.V.Venkatesh Mathan Kumar, M.D., (Psy)  
Professor, 
Institute of Mental health, 
Kilpauk, 
Chennai -10. 
A dissertation Submitted to 
THE TAMILNADU Dr. M.G.R MEDICAL UNIVERSITY, 
CHENNAI–32. 
 
In partial fulfillment of the requirement for the award of the degree of 
MASTER OF SCIENCE IN NURSING 
OCTOBER 2018 
  
5 
 
Acknowledgement 
 
  Without the blessing of God, his kindness, and support to overcome the 
adversities, this work is not possible. I thank the almighty for the blessing that has 
been bestowed upon me throughout the course of my study in this esteemed 
institution. 
Thanks are gratitude, saying thank you is more than good manners. It is a good 
spirituality 
I wish to express my sincere thanks to Dr. R. Jayanthi, M.D., F.R.C.P., 
(Glasg), Dean, Madras Medical College, Dr. Sudha shesayan,M.S.,Vice Principal, 
Madras Medical College, Chennai, for providing necessary facilities and extending 
support to conduct this study.  
           I extend my humble thanks to Mrs. A. Thahira Begum, M.Sc (N), M.B.A., 
M. Phil, Principal, College of Nursing, Madras Medical College, Chennai-3, for her 
guidance, and support to complete the study in a successful manner.   
It’s my great at pleasure to express my gratitude to my teacher  
Mr. M. Nithyanantham, M.Sc (N)., Reader, Vice principal I/C, HOD in Mental 
Health Nursing, College of Nursing, Madras Medical College, Chennai -03 for his 
constant guidance and support for completing this study in a successful manner. 
I also wish to express my thanks to Mr.k. Kannan M.Sc (N)., M.B.A. 
Nursing Tutor College of Nursing who incessantly encouraged me while carrying 
out my work. 
I express my thanks to all the faculty members of the College of Nursing, 
Madras Medical College, and Chennai.03 for their support and assistance in all the 
possible way to complete this study. 
I render my sincere thanks to Dr.P.Poorna Chandrika M.D., D.P.M., 
Director I/C Institute of Mental Health, Kilpauk, and Chennai.10 for granting 
permission to conduct this study. 
I deem it a great privilege to express my gratitude to Dr.V.Venkatesh 
Mathan Kumar., MD., Associate Professor, Institute of Mental Health, Kilpauk, 
Chennai -10, for his support and guidance for this study.  
I wish to express my gratitude to Nursing superintendent and Staff Nurses of 
Institute of Mental Health and for their support to completing this study successfully. 
6 
 
I acknowledge my sincere thanks to Mr. A.Vengatesan, M.Sc., Ph.D., 
Former DDME (Statistics), Directorate of Medical education, for his valuable 
suggestion and guidance in statistical analysis of data for this study. 
I extend my thanks to Mr. R. Ravi, M.A, B.L.I.Sc., Librarian, College of 
Nursing, Madras Medical College, and Chennai-03 for his co-operation and assistance 
which helps to gain in-depth knowledge regarding this study. 
My sincere thanks to my Study Participants of caregivers of antipsychotics 
patients, for their co-operation and enormous support for this study. 
 I express my gratitude to all my classmates who directly and indirectly 
supported me for completing this study successfully.  
I also extend my heartfelt and grateful thanks to my parents  
Mr. J.X. Bellarmin Fernando, Mrs. L. Jethzamine peeris, and my In laws 
Mr. K. Kondaiah, and Mrs. Munniamma, and moral support given by my Brothers 
and sisters, and my neighbour Ms. Divya  who gave timely help throughout. Without 
their support and love it’s not possible to complete my study successfully.   
        Of course, this work would not have been realizable but for the selfless and 
untiring support given by my husband K.Gajendrudu, who loves me 
unconditionally. Through every hardship or accomplishment, he has been behind me 
every step of the way and this work is a direct result of that. Very special thanks to 
my lovely daughters Joe Ansil and Monika Rosil who have made a lot of sacrifices  
to help me to achieve my goals .They have always been behind me in whatever I did 
and I would not be where I am today if it were not for them. 
 Finally I thank all whom I have not mentioned but nevertheless have been 
instrumental in the successful completion of the dissertation. 
 
 
 
 
 
ABSTRACT 
7 
 
 Antipsychotic   drugs  are  administered  to  control  the  symptoms  of  
psychosis  such  as  hallucinations  and  bizarre   or  paranoid  behavior. These   drugs 
calm without sedation or reduction in alertness. Acute extra pyramidal symptoms are 
like acute dystonia, akathisia and parkinsonism develop within hours or weeks after 
initiating or increasing doses of antipsychotics. Title: “Assess the effectiveness of 
psycho education module on knowledge regarding extra pyramidal symptoms among 
caregivers of patients on antipsychotic drugs attending outpatient department at IMH, 
Chennai”.Objectives: To assess the pre test and post test level of care givers 
knowledge  regarding extra pyramidal symptoms and find out the effectiveness of 
psycho education module and association of  post test knowledge score with A 
selected demographic variables .Methods and materials: A pre experimental design 
was chosen. Non probability convenient sampling technique used to select the sample. 
60 care givers were the sample. Glasgow Antipsychotic Side-effect Scale (GASS) was 
used to assess the care givers knowledge level. Results: In pre test, care givers 
knowledge score was 30.15after the administration of psycho education module their 
knowledge score was 13.63. Difference is 16.51.It was statistically significant at 
p<0.001 level. Conclusion: After psycho education module, the caregivers gained 
good level knowledge score. So Psycho education module has significant impact in 
gaining of knowledge score among care givers of antipsychotic patients. 
Key words: Psycho education module, knowledge, extra pyramidal symptoms, care 
givers. 
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CHAPTER - I 
INTRODUCTION 
“Medicines are nothing in themselves, if not properly used, but the very 
hands of the God, if employed with reason and prudence”              
                                                                                                    -       Herophilus 
  Psychosis is the most severe psychiatric disorder, in which there is 
marked impairment of behavior, serious inability to think coherently, 
comprehend and lack of insight. Positive symptoms include hallucinations, 
delusions and experiences that are not characteristic of normal mental life. 
Negative symptoms represent deficits in normal functions such as blunted 
affect, a social behavior and diminished motivation. Symptoms of impaired 
cognition include deficits in working memory, processing speed and social 
norms1. 
The mesolimbic pathway being associated with the positive symptoms 
and mesocortical  pathway associated with negative and cognitive symptoms2. 
Dopamine role in the causation of psychosis is complex. The positive 
symptoms are due to over activity in the mesolimbic dopaminergic pathway 
activating D2 receptors whereas negative symptoms may result from decreased 
activity in the mesocortical dopaminergic pathway where D1 receptors 
dominate3. 
An   antipsychotic   drugs  are  administered  to  control  the  symptoms  
of  psychosis  such  as  hallucinations  and  bizarre   or  paranoid  behaviour. 
These   drugs calm without sedation or reduction in alertness4. 
In the early 1950s, a few obscure chemicals tested in the back wards of 
mental hospitals ushered in the modern era of psychotropic drug treatments for 
mental disorders. Today, medication with antipsychotic drugs has become the 
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principal form of treatment used in mental hospitals, nursing homes, 
institutions for the retarded, and board and care homes that house the mentally 
ill. After the antipsychotics came lithium, the antidepressants, and the minor 
tranquilizers. Each year more than one-fifth of non institutionalized adults 
receive prescriptions for psychotropic drugs5. 
The first antipsychotic chlorpromazine was introduced in 19526. They 
act through D2 receptor blockade. These typical antipsychotics 
chlorpromazine, haloperidol or fluphenazine are effective in relieving positive 
symptom of the psychosis but have some serious limitations such as lack of 
efficacy against negative symptoms and adverse effects like extra pyramidal 
symptoms7. The inhibitory effects of dopaminergic neurons are normally 
balanced by the excitatory actions of cholinergic neurons in the striatum. 
Blocking dopamine receptors alters this balance, causing a relative excess of 
cholinergic influence, which results in extra pyramidal motor effects. The 
appearance of the movement disorders is generally time and dose dependent8. 
Advances in the treatment have emerged from discovery of newer 
antipsychotics also called as second generation antipsychotics potentially 
antagonize the 5HT2 receptor, block the D2 receptor less potently than typical 
antipsychotics. The development of these atypical antipsychotics such as 
Clozapine, Risperidone, Olanzapine, Quetipine in 1990’s fulfilled great 
expectations in treatment of psychosis by reducing the extra pyramidal 
symptoms 9. 
Antipsychotics induced extra pyramidal symptoms include a variety of 
movement disorders Acute extra pyramidal symptoms are like acute dystonia, 
akathisia and parkinsonism develop within hours or weeks after initiating or 
increasing doses of antipsychotics. Tardive dyskinesia and tardive dystonia are 
delayed onset syndromes and usually develop after a prolonged use of 
antipsychotics10.  The term “neuroleptic” meaning “to fix or hold a neuron” 
was used to describe the neurological adverse effect of conventional 
antipsychotics rather than their therapeutic effects11. 
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Caring  for  someone  with   a mental  disorders  can  affects  the  
dynamics  of  family. It  takes  up  most  of  the  carers  time  and  energy.  The  
family  responsibility  is   providing  care  for  people  with  mental  disorders  
has  increased  in  past  three  decades. This  has  been  mainly  due  to  trend  
towards  community  care  and  de-hospitalization  of  psychiatry  patients 12. 
Relatives are usually involved in caring for the patients who are 
receiving antipsychotic drugs. Thus it is essential that all caregivers understand 
the medication, side effects, precautions and the caregiver’s role. Investigators 
have proved that educating caregivers on the importance of compliance to 
antipsychotic drugs, side effects and their role in caring for mentally ill patients 
can reduce relapse13. Caregiver’s stress, burden and sense of being 
overwhelmed by the care giving roles have been linked to patient’s persistent 
behavioural problems and caregiver’s perceived or actual inability to handle 
them. So their role is important in caring for their mentally ill relatives14. 
1.1     NEED FOR STUDY: 
In  India   the  reported  rate  of  mental  illness  is  100  per  thousand  
population .It   has been  estimated  that  20% - 50%  of  any  patient  
population  is  at least  partially  complaint  and  that  in  patients   with  
schizophrenia  and  related  psychotic  disorders  rates  run as  high as 70%-
80%.   The    WHO  is  currently  undertaking   a  global  survey of  26  
countries  in  all   regions of  the  world ,  based  on  ICD  and   DSM criteria.  
The  first  published  figures  on  the  14  country  surveys  completed  to  date,  
indicate  that,  of  those   disorders  assessed,  anxiety disorders  are  the  most  
common  in  all  but  1   country (prevalence in the prior     12 - month period 
of 2.4% to 18.2%) and  mood  disorders  next  most  common  in  all  but  2 
countries  (12-month prevalence of 0.8% to 9.6%),  while  substance disorders 
(0.1%–6.4%)  and  impulse-control disorders (0.0%–6.8%)  were consistently  
less prevalent. It  has been  estimated  that  of   largest  prevalence  rate  of  
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psychiatric  illness . In the  U.S  find  the  anxiety  disorders  affect  15.7  
million  people  in  united  states  each  year15.  
The  United States,  Colombia,  the  Netherlands  and  Ukraine  tended  
to  have  higher  prevalence  estimates  across  most classes of disorder,  while 
Nigeria,  Shanghaisi   and  Italy  were  consistently  low , and  prevalence  was  
lower  in  Asian countries  in  general. Cases of  disorder  were  rated  as  mild  
(prevalence of 1.8%–9.7%),  moderate (prevalence of 0.5%–9.4%) and  serious 
(prevalence of 0.4%–7.7%) .However,  these  are  widely  believed  to  be  
underestimates,  due  to  poor  diagnosis  (especially  in  countries  without  
affordable  access to mental  health  services) and  low reporting rates, in  part  
because  of the predominant use of self-report data, rather than semi-structured 
instruments  such  as the  Structured Clinical Interview for DSM-IV (SCID);  
actual  lifetime  prevalence  rates  for  mental disorders  are  estimated  to  be  
between  65% and 85%16. 
The incidence of psychotic disorders across 17 areas in six countries -- 
the UK, France, Italy, the Netherlands, Spain and Brazil -- using comparable 
methodology. Their data was drawn from people aged 18-64 who contacted 
mental health services after a suspected first psychotic episode, which included 
2,774 incident cases in total. They found the overall incidence of psychotic 
disorders to be 21.4 per 100,000 person-years, but discovered wide variations 
between different areas, from a low of 6.0 per 100,000 person-years in the rural 
area around Santiago (Spain), to a high of over 45 in inner-city Paris and 
Southeast London. This variation could not be explained by differences in the 
age, sex and ethnic composition of the population across these areas17 
A study revealed that the extra pyramidal symptoms were more 
commonly seen in males (62.85%), the age of incidence of maximum in the 
age group of 34.28, Maximum was seen among the patients on the Risperidone 
(45.7%), Involvement of the extremities was common (42.85%) and 64.28% of 
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individuals had moderate severity and 54.28% of individuals were aware of the 
extra pyramidal symptoms which provided mild distress18. 
As a part of the pharmaco vigilance programme of India, the authors 
have assessed 10 physician-reported cases of EPS among the 1,830 patients 
who were prescribed risperidone within  the time period of January 2012-
December 2014 in a tertiary care hospital in South India. Causality, severity, 
and preventability assessments of adverse reaction were done as per Naranjo's, 
Hartwig's, and Thornton's scale respectively. 10 cases, a dose-dependent 
occurrence of EPS was noted in all and the time duration for development of 
EPS ranged from 1 week to 2 years. Four patients developed EPS at a dose of 
6–8 mg, 4 developed at a dose of 4–6 mg, and the remaining 2 developed at 2 
and 1 mg19 
A study revealed that the extra pyramidal symptoms were more 
commonly seen in males (62.85%), the age of incidence of maximum in the 
age group of 34.28, Maximum was seen among the patients on the Risperidone 
(45.7%), Involvement of the extremities was common (42.85%) and 64.28% of 
individuals had moderate severity and 54.28% of individuals were aware of the 
extra pyramidal symptoms which provided mild distress20. 
Due to short hospital stay and the involvement of the family in the care 
of the patient, the contact of the patient with healthcare personnel is minimal. It 
is the family which stays with the patients for 24 hours of the day helping the 
patient meet his/her needs. So it is very important that caregivers receive 
sufficient knowledge as to how to care for their relatives who are on 
antipsychotic drugs. 21 
1.2    STATEMENT OF THE PROBLEM: 
“Assess the effectiveness of psycho education module on knowledge 
regarding extra pyramidal symptoms among caregivers of patients on 
antipsychotic drugs attending outpatient department at IMH, Chennai” 
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1.3    OBJECTIVES OF THE STUDY: 
1. To assess the socio demographic variables and pre test knowledge of 
care giver regarding extra pyramidal symptoms.. 
2. To determine the pre test and post test knowledge of care giver 
regarding extra pyramidal symptoms. 
3. To find association between post test knowledge score and selected 
demographic variables. 
1.4   OPERATIONAL DEFINITIONS: 
1) Assess: It is refers to the statistical analysis of knowledge through 
MGASS among care givers. 
2) Effectiveness:  Effectiveness is the extent to which an activity fulfils its 
intended purpose or function.      
3) Psycho education module:  It is defined as well planned and arranged 
programme through which knowledge is provided to subjects and 
improvement is based on outcome. 
4) Knowledge: It is defined as an expertise, and skills acquired by a person 
through experience or education; the theoretical or practical 
understanding of a subject. 
5) Extra pyramidal symptoms: Extra pyramidal symptoms (EPS) are 
various movement disorders such as acute dystonic reactions, pseudo 
parkinsonism or akathisia suffered as a result of taking dopamine 
antagonists, usually antipsychotic (neuropleptic) drugs, which are often 
used to control psychosis. 
6) Caregivers:  It refers to the people who are taking care of patients 
receiving antipsychotic drugs 
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7) Antipsychotics:Drugs which  is used to treat the psychotic symptoms 
and also produce EPS. 
8) Psychiatric hospital: It refers to Institute of Mental Health l where the 
psychiatric patients are attending OPD  
 1.5    ASSUMPTION: 
The proposed study assumes that: 
Care givers doesn’t have enough knowledge regarding extra pyramidal 
symptoms, after psycho education module the care givers will gain more 
knowledge regarding extra pyramidal symptoms 
1.6   HYPOTHESIS: 
H1: The mean post test knowledge score of caregivers undergoing the 
structured teaching programme is more than the mean pre-test score. 
 H2: There will be a significant association between pre-test scores of 
caregivers and with selected demographic variables.  
1.7      DELIMITATIONS OF THE STUDY: 
• The study is limited to the caregivers of patients receiving 
antipsychotics attending the OPD at IMH, Chennai. 
• The period of study is limited to 4 weeks. 
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CHAPTER -II 
2.1. REVIEW OF LITERATURE 
           The review of literature is defined as a broad comprehensive, in depth 
systematic and critical review of scholarly publications, unpublished scholarly 
print materials, audio visual materials and personal communication. Literature 
having a direct bearing on the present subject was reviewed in order to have an 
insight into the selected problem area and build the foundation of the study thus 
becoming familiar with the related article, studies, techniques, tools used and 
problems encountered by previous researchers. These helped in planning the 
framework design, developing tool and designing the interview schedule. 
The  review  of  literature  for  the  present  study  has   been  organised  under  
the  following   headings:- 
    The studies under review are organised under three headings. 
2.1.1  Literature  review  related  to  knowledge  of  family   members  
on  care  of  patients  receiving  antipsychotic  therapy. 
2.1.2 Literature review related to the side effects of antipsychotic 
therapy. 
2.1.3 Literature review related to EPS by antipsychotic drugs.  
2.1.1.  Literature   Review  related  to  knowledge  of  family  members  on  
care  of  patients  receiving  antipsychotic  therapy   
                Vimala D R(2016)  conducted descriptive  study  was     to  assess   
the  knowledge  ,attitude   and  practice  of  family members  of  client  with  
mental illness among Medicaid  patient with schizophrenia, at community  
setting  of   California.  A   size   sample of   100   family   members was 
selected   with purposive   sampling technique.  Data    was collected with 
structured   questionnaires with   four modules. The study result  shows  that   
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78%  were  able  to identify  a  cause  or  precipitating  the  onset  of  illness 
,97% of  that  mental  illness  is curable with  medication .80%  of  them  
allowed  the  mentally ill client to attend   the  social  gathering  or visit  places 
’25%  0f  the  participants  objected  to  marrying  family member  of  a  
mentally  ill  person. The  mean  score was  statistically  higher  among  those  
with secondary  level  of  education(M= 16.6,SD=  4.9)  in  comparison  with  
those    with  primary   level of  education (M= 13.9,SD= 4.50) .family  
members of  urban  area  scored significantly  higher(M= 17.2,SD= 4.5)than  
those  from  rural area (m= 14.3,sd= 4.8)22 
            Mao –Sheng Ran ,Meng – Zea Xang, Cecilia Lai – wan,Julian Leff, 
et al  (2016) conducted descriptive  study was to explore the characteristics  
and efficacy of psycho educational  family  intervention    for  persons of  
schizophrenia   in  rural  community  settings, China  .A  sample  size  of   326  
were  selected  by  cluster  randomised  sampling  technique . The tool  of  this  
study  involved  drug  treatment  and  psycho  educational  family intervention.  
The study  results  show that   a  gain  in   knowledge , a  change  in  relatives  
caring  attitude  towards  the patients  and  increase  in  psycho educational  
family group (P< 0.05,0.001)  most important  relapse rate  over  9  months  in  
this  group. (16.3%)  was  half  of  that  drug  group  only (37.8%)  and  just 
over one  quarter of  that control group (61.5%)(p<0.05) moreover  there were 
also no significant  differences  of  demographics  for  the  main  carers23.  
          Sailesh P. (2015)   conducted  descriptive   study  was to  assess  the  
impact  of  non adherence  and other factors  associated  with   resources   and  
cost   incurred  by  people  with  schizophrenia. 658 samples were studied and 
it patients in other types of institution. Cross-sectional survey method was used 
and data was collected with the help of a structured interview schedule. The 
study was conducted to assess the impact of non adherence and other factors 
associated with resource use and costs incurred by people   The  study  results  
shows that  the  rate  of  reported  non-adherence  was  lower  in the sub  
sample  of  patients  resident  in  hospital (11.2%)  compared  with  (21.2%) 24.. 
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Wyatt RG (2017) conducted study was to examine Pope A, Adams C, 
Paton C, Weaver T.  (2016) conducted an exploratory descriptive study 
design was utilized, whereby a sample of nursing staff was given a 
questionnaire developed to determine knowledge about antipsychotic drugs and 
their use with the older persons. Questionnaires were distributed to 100 nursing 
staff, including registered general nurses, registered mental nurses, nursing 
assistants and care assistants. Of the 100 questionnaires distributed, 62 were 
returned and 57 were completely substantially enough for data analysis. Results 
indicated that the use of antipsychotic drugs within the psychiatric hospital 
setting was substantial, with 43.7% of patients receiving antipsychotic drugs, 
for an average length of time of 1.8 years. It was concluded that nursing staff 
participants from all three work settings revealed a number of significant 
knowledge gaps, particularly with regard to appropriate indications for 
antipsychotic drugs with older persons and the side effects of antipsychotic 
drugs25.   
2.1.2  Literature  Review  related  to  side effects of  antipsychotic  therapy 
relationships between dopamine D (2) receptor binding in both substantia nigra 
and temporal cortex with extra pyramidal symptoms among antipsychotic-
treated patients with schizophrenia.  Previous studies have highlighted a central 
role for nigral dopamine D (2) receptors in the control of motor functions. 
Single-photon emission-computed tomography was used to determine 
dopamine D (2/3) apparent binding potential in 13 antipsychotic-treated (seven 
with clozapine, four with olanzapine and two with haloperidol) patients with 
schizophrenia. Extra pyramidal symptoms were assessed with the Simpson and 
Angus Scale (SAS).  Result was found that statistically significant correlation 
was observed between dopamine D(2/3) receptor apparent binding potential in 
the substantia nigra and extra pyramidal side-effects. Conclusion supports the 
role of dopamine D (2) auto receptors in substantia nigra regarding drug-
induced movement disorders26.   
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Miller CH, Mohr F, Umbricht D, et al (2017) conducted study was to 
provide information on patient-reported side effects from a cross-section of 
real-world patients. Specifically, data on side effects were tabulated for patients 
taking at least one of the following atypical antipsychotic medications: 
Aripiprazole, Olanzapine, Paliperidone, Quetiapine, Risperidone, or 
Ziprasidone. Approximately 54 percent of the 353 respondents reported having 
experienced a side effect as a result of taking an atypical antipsychotic 
medication. Most common side effects mentioned included the following: 
weight gain/hunger, tiredness/lethargy, and lack of coordination/muscle 
problems, such as tenderness twitches, and tremors. The  result was 172 
patients who listed at least one side effect, 30 to 35 percent of patients reported 
weight gain always hungry and/or tiredness/lethargy.  Lack of coordination 
and muscle problems, such as twitches, tenderness, or tremors, were mentioned 
by 5 to 10 percent of patients. It was concluded that antipsychotic-related side  
effects continue to be highly prevalent among atypical antipsychotic exposed 
patients27. 
Raja. M (2017) conducted study was to develop an evidence base for 
recommendations on the use of atypical antipsychotic for patients with 
schizophrenia where 12 649 patients in 52 randomized trials comparing 
atypical antipsychotic with  The results of Meta-regression suggested that dose 
of conventional antipsychotic explained the heterogeneity. It was concluded 
that there is no clear evidence that atypical antipsychotic are more effective and 
better tolerated than conventional antipsychotics. Conventional antipsychotics 
should usually be used in the initial treatment of an episode of schizophrenia 
unless the patient has previously not responded to these drugs or has 
unacceptable extra pyramidal side effects28.  
Anirudh  G (2017) conducted   descriptive   study was to investigate   
the   effectiveness   of   training  and   structured  assessment  on  clinical  and  
social  outcome  of  patient  receiving  maintains   medication   of   depot   
antipsychotics  among  nurses  working  in south  Gujarat,  India. A sample of 
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forty nine nurses was selected with simple random   technique.   Data was 
collected with help of structured questionnaires. Results  shows  that  40%  of  
majority of  practice  nurses  received  scant  referral   information  and worked  
without  protocols.  There was a unexpected increase awareness of problem of 
severely mentally ill.29 
Tuppurainen H, Kuikka JT, Viinamaki H, Husso M, Tiihonen J. 
(2016) conducted study was in Canada, Ontario to compare the  incidence of 
admissions to hospital for stroke among older adults with dementia receiving 
atypical or typical antipsychotics. As a sample, 32,710 older adults (< 65 years) 
with dementia (17845 dispensed an atypical antipsychotic and 14865 dispensed 
a typical antipsychotic) were selected. The results indicated that after 
adjustment for potential confounders, participants receiving atypical 
antipsychotics showed no significant increase in risk of ischemic stroke 
compared with those receiving typical antipsychotics. This finding was 
consistent in a series of subgroup analysis, including ones of individual atypical 
antipsychotic drugs and selected subpopulations of the main cohorts. It was 
concluded that older adults with dementia who take atypical antipsychotics 
have a similar risk of ischemic stroke to those taking atypical antipsychotics30    
Kennedy , Mion (2016) conducted    descriptive   study   was  to  
evaluate   knowledge of antipsychotic  drugs  use  with psychiatric  patients   
among  nurses  in  selected  nursing  home  in  US,  A  sample  size  of  90 
nurses  is selected  with  randomised  sampling  technique  . Data  was  
collected  with  the  help of  structured questionnaires.  The   result shows  that  
only  27%   of nursing staff  responding  in  a  satisfactory way. 31.  
Pierre JM.  (2016) conducted study on atypical antipsychotic are 
indicated for the treatment of refractory schizophrenia, and in some cases, 
bipolar disorders; they are also used off-label for symptoms such as agitation, 
anxiety, psychotic episodes, and obsessive behaviors, as well as in children and 
the elderly. The findings was done on a recent meta-analysis of 150 double-
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blind, randomized controlled trials (N = 21,533) raised questions about the 
notion that atypical antipsychotic as a class are truly superior to typical 
antipsychotic in terms of efficacy and side-effects.  It was concluded that he 
older agents have been associated with adverse effects such as extra pyramidal 
symptoms, severe movement disorders, and sudden cardiac death, among 
others32.   
Levenson. A  (2016) conducted  exploratory  study  was  among     
nurses  knowledge       of  antipsychotic   drug  use   with  older persons  within  
the three  units  of  the  psychiatric hospital  were  collected  directly  from  
patient  medical  and  nursing  case  notes,  from  which   the   nurses  recorded   
their  data  on  care  plans   regarding   the   patient’ s  progress.   Data   
analysis  procedures   Simple   descriptive  statistics    were  calculated  for  
demographic  variables  and  the  questionnaire  responses.  The  three  units  of 
the   psychiatric hospital  had  265  patients,  and  43.7% (n=114)  were   
receiving  antipsychotic   medications  at  the  time  of  the study . The  reasons  
given  for the  use  of  antipsychotic  medications  included  the  following:   
agitation/restlessness (62.8%, n=72)  severe anxiety (41.3%, n=48)    
behavioral problems (18.9%, n=22)    psychosis (13.7%, n=16)   depression 
(8.6%, n=10)   cognitive impairment (6.0%, n=7)   insomnia (3.4%, n=4)    
alcohol misuse (1.7%, n=2)   self-neglect (0.8%, n=1).  The  average  length  of  
time  that  the  hospital  patients  had been receiving  antipsychotics  was  22.0  
months,  with  a   range  of  one  month  to  108  months.  Interestingly,  almost  
36% (n=41)  of  the   hospital  patients   receiving  antipsychotics  had  
documentation  in  the   case  notes  of  conditions  that  might  be  indicative  
of  side-effects  due  to antipsychotic drug use . Ability  to  correctly  identify  
antipsychotic drugs,  a  majority  of  nursing staff  could  correctly  identify  
antipsychotic drugs  by  name,  with  a  range  from  60.9%  (trifluoperazine)  
to  75.0% (promazine).  A  surprising  number  of  nursing staff  also  indicated  
that  they    ‘didn’t  know’ whether  an  actual antipsychotic  drug  was  in fact  
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an  antipsychotic,  with  a   range  from  25.0% (promazine)  to  34.1% 
(trifluoperazine)33. 
William Honer G, (2015) study was taken to identify the safety and 
tolerability of antipsychotic in recent clinical studies. A survey was conducted 
of all 167 eligible studies published between 2002 and 2007 on the Cochrane 
Schizophrenia Group register and the result was extra pyramidal side-effects 
(EPS) and weight gain were most frequently assessed. A minority of reports 
addressed metabolic abnormalities, aversive subjective experiences and sexual 
dysfunction. Published rating scales were frequently used to evaluate EPS, but 
systematic methods were rarely applied to other treatment-emergent problems. 
The definition of individual adverse effects and the manner of reporting were 
inconsistent. It was concluded that the way in which safety and tolerability data 
are collected and reported in clinical studies does not allow for fair and 
meaningful comparison of the relative risk profiles of individual antipsychotic 
drugs34   
Lili Kopala C (2014) study was conducted on the important role of the 
mental health nurse in facilitating adherence has been acknowledged, however, 
there has been little exploration of how nurses themselves perceive this aspect 
of their role. A qualitative study was conducted to explore the perceptions of 
mental health nurses employed in inpatient settings regarding their role in 
facilitating medication adherence. Focus groups conducted with 22 nurses from 
three inpatient settings in metropolitan Melbourne35 
Cuningham Owens DG (2014) conducted study indicated that young 
males have an increased susceptibility to develop extra  pyramidal side effects, 
although the effects can and do occur in both sexes. The reasons for increased 
risk in males are not fully known but may be related to increased muscle mass 
in men. The incidence of extra pyramidal side effects also appears to be dose 
dependent. In addition, intramuscular dosing of neuroleptics may increase the 
chances of causing extra pyramidal side effects  study stated that the traditional 
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anti-psychotic agents block receptors for dopamine in the CNS, and they all 
can cause serious movement disorders referred to as extra pyramidal reactions. 
Nurse is often involved in the routine screening and monitoring clients for the 
presence of extra- pyramidal side effects36.  
Wyatt RG(2014) conducted  study was conducted on the treatment of 
schizophrenia which changed drastically with the discovery of antipsychotic 
medications in the 1950s, the release of clozapine in the US in 1989 and the 
subsequent development of the atypical or novel antipsychotic. EPS thought to 
have a significant impact on subjective tolerability and adherence with 
antipsychotic therapy in addition to impacting function. Unlike conventional 
antipsychotic medications, atypical antipsychotic have a significantly 
diminished risk of inducing acute EPS at recommended dose ranges. This paper 
reviews the available evidence regarding the incidence of acute EPS and 
Tardive syndromes with atypical antipsychotic therapy. Estimates of incidence 
are subject to several confounds, including differing methods for detection and 
diagnosis of EPS, pre treatment effects and issues surrounding the 
administration of antipsychotic medications. Results showed the use of atypical 
antipsychotic as first line therapy for the treatment of schizophrenia is based 
largely on their reduced risk of EPS compared with conventional antipsychotic. 
It was concluded that the EPS advantages offered by the atypical antipsychotic 
must be balanced against other important adverse effects, such as weight gain 
and diabetes mellitus, now known to be associated with these drugs37.  
Miller CH, Mohr F, Umbricht D (2014) conducted study to assess the 
faced with these numerous potential side effects, many patients on traditional 
antipsychotic drugs find it difficult to tolerate their medication and they stop 
taking it. Patients who are helped by antipsychotic drugs cannot be persuaded 
to continue taking the drugs when they are feeling well. The American 
Psychiatric Association estimates that 50% of schizophrenic patients stop 
taking their medication within six months of discharge because of troublesome 
side effects such as muscle spasms, restlessness and tremors. Statistics gathered 
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at Oregon Health Sciences University show that 52% of schizophrenic patients 
are readmitted within a year of hospital discharge, and this figure applies only 
to patients with no previous history of readmission. Statistics worsen with each 
cycle of discharge and readmission. One study placed the relapse rate for 
schizophrenic patients who were noncompliant with medication at76% within 
one year38. 
Sink KM, Holden KF, Yaffe K. (2016) conducted a study was done on 
the behavioral and psychological symptoms of dementia (BPSD) and the 
effectiveness of antipsychotic drugs which are prescribed mostly. A qualitative 
review of the data was done on the efficacy and safety of antipsychotic drugs 
for BPSD and examined for safety issues with an especial focus on recent 
research. Results were found that typical and atypical antipsychotic drugs both 
attenuate the severity of BPSD; both categories of drugs increase the risk of 
cerebrovascular and other adverse events, as well as the risk of death. The risk 
appears greater with the typical drugs, with higher doses, and during the initial 
weeks of treatment. Both drug- and patient-related factors appeared to mediate 
this increase in risk. It was concluded that antipsychotic drugs should be 
considered for BPSD only if there is a specific need, decision-making should 
be individualized and documented after a risk-benefit analysis and verified for 
extra pyramidal symptoms39.   
John Kamin, M.D., Sumita Manwani, M.D. and Douglas Hughes, 
M.D(2016) investigated a study was conducted on the movement disorders in 
first-episode psychosis are increasingly recognized and compared antipsychotic 
exposed (< 12 weeks) with non exposed first-episode patients, and report 
prevalence as well as clinical and demographic variables associated with extra 
pyramidal dysfunction. Data are baseline assessments from a multicentre, 
international drug trial of first-episode psychosis (n = 535). Analysis included 
the extra pyramidal Symptom Rating Scale, Premorbid Adjustment Scale, and 
the Positive and Negative Syndrome Scale. Of non-exposed patients, 28.1% (n 
= 47/167) had at least one mild sign of extra pyramidal dysfunction, as did 
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46.3% (n = 169/365) of previously exposed patients. Hypo kinetic 
Parkinsonism was the most prevalent disorder. The severity of movement 
disorders and negative symptoms were correlated and antipsychotic exposure 
was associated with extra pyramidal signs, the results indicate that many first-
episode patients with no exposure to antipsychotic also had extra pyramidal 
dysfunction40.   
 Plesnicar BK (2016) revealed a study was conducted to examine 
relationships between dopamine D (2) receptor binding in both substantia nigra 
and temporal cortex with extra pyramidal symptoms among antipsychotic-
treated patients with schizophrenia.  Previous studies have highlighted a central 
role for nigral dopamine D (2) receptors in the control of motor functions. 
Single-photon emission-computed tomography was used to determine 
dopamine D (2/3) apparent binding potential in 13 antipsychotic-treated (seven 
with clozapine, four with olanzapine and two with haloperidol) patients with 
schizophrenia. Extra pyramidal symptoms were assessed with the Simpson and 
Angus Scale (SAS).  Result was found that statistically significant correlation 
was observed between dopamine D(2/3) receptor apparent binding potential in 
the substantia nigra and extra pyramidal side-effects. Conclusion supports the 
role of dopamine D (2) auto receptors in substantia nigra regarding drug-
induced movement disorders41.   
Caccia S, Pasina L, Nobili(2015) conducted a study was to provide 
information on patient-reported side effects from a cross-section of real-world 
patients. Specifically, data on side effects were tabulated for patients taking at 
least one of the following atypical antipsychotic medications: aripiprazole, 
olanzapine, paliperidone, quetiapine, risperidone, or ziprasidone. 
Approximately 54 percent of the 353 respondents reported having experienced 
a side effect as a result of taking an atypical antipsychotic medication. Most 
common side effects mentioned included the following: weight gain/hunger, 
tiredness/lethargy, and lack of coordination/muscle problems, such as 
tenderness twitches, and tremors. The  result was 172 patients who listed at 
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least one side effect, 30 to 35 percent of patients reported weight gain always 
hungry and/or tiredness/lethargy.  Lack of coordination and muscle problems, 
such as twitches, tenderness, or tremors, were mentioned by 5 to 10 percent of 
patients. It was concluded that antipsychotic-related side  effects continue to be 
highly prevalent among atypical antipsychotic exposed patients42. 
Seidal S, Aigner M, Ossage(2015) conducted a study was to develop an 
evidence base for recommendations on the use of atypical antipsychotic for 
patients with schizophrenia where 12 649 patients in 52 randomized trials 
comparing atypical antipsychotic with  The results of Meta-regression 
suggested that dose of conventional antipsychotic explained the heterogeneity. 
It was concluded that there is no clear evidence that atypical antipsychotic are 
more effective and better tolerated than conventional antipsychotics. 
Conventional antipsychotics should usually be used in the initial treatment of 
an episode of schizophrenia unless the patient has previously not responded to 
these drugs or has unacceptable extra pyramidal side effects43. 
Lepping P, (2015) investigated study was done in Canada, Ontario to 
compare the incidence of admissions to hospital for stroke among older adults 
with dementia receiving atypical or typical antipsychotics. As a sample, 32,710 
older adults (<65 years) with dementia (17845 dispensed an atypical 
antipsychotic and 14865 dispensed a typical antipsychotic) were selected. The 
results indicated that after adjustment for potential confounders, participants 
receiving atypical antipsychotics showed no significant increase in risk of 
ischemic stroke compared with those receiving typical antipsychotics. This 
finding was consistent in a series of subgroup analysis, including ones of 
individual atypical antipsychotic drugs and selected subpopulations of the main 
cohorts. It was concluded that older adults with dementia who take atypical 
antipsychotics have a similar risk of ischemic stroke44.  
 
 
32 
 
2.1.3 Literature review related to EPS by antipsychotic drugs.  
            Sink KM, Holden KF, Yaffe K (2017) conducted study was on extra 
pyramidal side effects such as dystonias, parkinsonism, and akathisia. 
Dystonias are prolonged and unintentional muscular contractions of voluntary 
or involuntary muscles. Neuroleptic-induced Parkinsonism is characterized by 
the triad of tremor, rigidity, and bradykinesia; Akathisia is characterized by a 
patient's subjective sense of restlessness, along with such objective evidence of 
restlessness as pacing or rocking. Extra pyramidal side effects were done on 
random sampling of about 100 patients receiving antipsychotics. 40% of them 
reported with dystonia and manifested, albeit laryngeal dystonia or dystonias of 
other musculature related to breathing. 30% manifested with severe muscular 
rigidity, fever, an altered level of consciousness, and autonomic instability 
characterize neuroleptic malignant syndrome. 20% of them reportedwith 
akathesia and 10% with Tardive dyskinesia45.  
           John Kamin, M.D., Sumita Manwani, M.D. and Douglas Hughes 
(2017) investigated study was taken to identify the safety and tolerability of 
antipsychotic in recent clinical studies. A survey was conducted of all 167 
eligible studies published between 2002 and 2007 on the Cochrane 
Schizophrenia Group register and the result was extra pyramidal side-effects 
(EPS) and weight gain were most frequently assessed. A minority of reports 
addressed metabolic abnormalities, aversive subjective experiences and sexual 
dysfunction. Published rating scales were frequently used to evaluate EPS, but 
systematic methods were rarely applied to other treatment-emergent problems. 
The definition of individual adverse effects and the manner of reporting were 
inconsistent. It was concluded that the way in which safety and tolerability data 
are collected and reported in clinical studies does not allow for fair and 
meaningful comparison of the relative risk profiles of individual antipsychotic 
drugs46.   
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              Plesnicar BK, (2016) study indicated that young males have an 
increased susceptibility to develop extra  pyramidal side effects, although the 
effects can and do occur in both sexes. The reasons for increased risk in males 
are not fully known but may be related to increased muscle mass in men. The 
incidence of extra pyramidal side effects also appears to be dose dependent. In 
addition, intramuscular dosing of neuroleptics may increase the chances of 
causing extra pyramidal side effects  study stated that the traditional anti-
psychotic agents block receptors for dopamine in the CNS, and they all can 
cause serious movement disorders referred to as extra pyramidal reactions. 
Nurse is often involved in the routine screening and monitoring clients for the 
presence of extra- pyramidal side effects47.  
Caccia S, Pasina L, Nobili A. (2016) study was conducted on the treatment 
of schizophrenia which changed drastically with the discovery of antipsychotic 
medications in the 1950s, the release of clozapine in the US in 1989 and the 
subsequent development of the atypical or novel antipsychotic. EPS thought to 
have a significant impact on subjective tolerability and adherence with 
antipsychotic therapy in addition to impacting function. Unlike conventional 
antipsychotic medications, atypical antipsychotic have a ignificantly 
diminished risk of inducing acute EPS at recommended dose ranges. This paper 
reviews the available evidence regarding the incidence of acute EPS and 
tardive syndromes with atypical antipsychotic therapy. Estimates of incidence 
are subject to several confounds, including differing methods for detection and 
diagnosis of EPS, pretreatment effects and issues surrounding the 
administration of antipsychotic medications. Results showed the use of atypical 
antipsychotic as first line therapy for the treatment of schizophrenia is based 
largely on their reduced risk of EPS compared with conventional antipsychotic. 
It was concluded that the EPS advantages offered by the atypical antipsychotic 
must be balanced against other important adverse effects, such as weight gain 
and diabetes mellitus, now known to be associated with these drugs48.  
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Clive Adams, E (2016) conducted a comparative study was done on the 
prevalence and severity of extra pyramidal side effects (EPSs) in 106 patients 
treated with Clozapine, 23 patients treated with Risperidone, and 42 patients  
treated with conventional antipsychotics for at least 3 months. Authors 
examined differences between the 3 groups with regard to Akathisia and extra 
pyramidal motor side effects. The results were pointed as prevalence of 
Akathisia was 7.3% in the Clozapine group, 13% in the Risperidone group, and 
3.8% in the group treated with conventional antipsychotics49.  
Charles R. (2016) conducted a cross-sectional descriptive study 
conducted at Katsina State Psychiatric Hospital. A total of 129 caregivers who 
presented consecutively. This was  developed to assess caregiver burden in 
relatives of patients with chronic mental  illnesses. The factors include the 
caregiver's health, psychological wellbeing, finances, social life, stigma details, 
and relations. The instrument has been used to assess caregiver burden not only 
in dementia but also in schizophrenia. Results were found that a high level of 
caregiver burden was found in 61 (47.3%) respondents. A higher level of 
caregiver burden was significantly associated with place of residence and 
family size.  Large proportions of respondents were experiencing a high level 
of burden; this was significantly associated with family size and place of 
residence50.  
Martyn-Yellowe IS. (2016) revealed a study on the prevalence of usage 
of antipsychotic drugs in the USA was reported at 13.9% among individuals 
aged 40 years and older. Global estimates for 2001 showed that, worldwide, 
approximately 10 million people suffered from dementia; 8 million are with 
Parkinsonism 6 million suffering with Alzheimer’s disease and overall 24.3 
million people are suffering with neuropsychiatry disorders and 60.1% of all 
people with dementia lived in developing countries. In India, the prevalence of 
usage of antipsychotic drugs lies in the range of 1.8 to 3.6% among individuals 
aged 60 to 65 years51.  
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Kuipers L. (2015) investigated a study was done on prevalence of acute 
extra pyramidal signs and symptoms in patients treated with clozapine, 
risperidone, and conventional antipsychotics. The point-prevalence of rigidity 
and cogwheeling (EPSs) respectively was 4.9% and 2.4% in the clozapine 
group, 17.4% and 17.4% in the risperidone group, and 35.7% and 26.2% in the 
group treated with conventional antipsychotics. Results indicate that 
risperidone is superior to conventional neuroleptics in that it causes fewer 
EPSs. In comparison to clozapine, risperidone produced EPS levels that are 
intermediate between clozapine and conventional antipsychotic drugs52.                                             
Greenberg JS, Greenly JR, McKean D, Brown R, Griffin-Francell 
C. (2015) conducted study on nursing personnel research has documented the 
widespread use of antipsychotic drugs by nursing staff with older persons, 
although less is known about the knowledge that nurses actually have about 
these drugs. An exploratory descriptive study design was utilized, whereby a 
sample of nursing staff was given a questionnaire developed to determine 
knowledge about antipsychotic drugs and their use with the older persons. 
Questionnaires were distributed to 100 nursing staff, including registered 
general nurses, registered mental nurses, nursing assistants and care assistants. 
Of the 100 questionnaires distributed, 62 were returned and 57 were completely 
substantially enough for data analysis. Results indicated that the use of 
antipsychotic drugs within the psychiatric hospital setting was substantial, with 
43.7% of patients receiving antipsychotic drugs, for an average length of time 
of 1.8 years. It was concluded that nursing staff participants from all three work 
settings revealed a number of significant knowledge gaps, particularly with 
regard to appropriate indications for antipsychotic drugs with older persons and 
the side effects of antipsychotic drugs53.   
Tsang HWH, Tam PKC, Chen F, Chang M. (2015) conducted 
comparative study was done to measure caregiver attitudes to antipsychotic 
drugs and their adverse side effects and comparing these with the attitudes of 
the general population. Analysis and comparison of two representative samples 
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were taken, one comprising 100 caregivers and the other 791 individuals 
randomly selected from the general population. The setting was on the German 
speaking cantons of Switzerland. Results showed significantly more positive 
attitudes towards anti-psychotic drugs than the general public. In particular the 
risk of dependency was assessed as 'low' by caregivers (80%), in contrast to 
only 18% of the general population sample. It was concluded that effective 
management of side effects play a vital aspect of patient career and caregivers 
need to be aware that their mentally ill patients are likely to be confronted with 
extremely negative public attitudes towards antipsychotic medication and with 
strong pressure to stop taking their medication in the event of side-effects54.  
                Kirgaval RS, Revanakar S, Srirangapattna C (2015)  conducted 
study was on January 15, 2009 New England Journal of Medicine addressing 
the use of atypical, antipsychotic drugs which carried a risk of sudden cardiac 
death.  Atypical antipsychotic are indicated for the treatment of refractory 
schizophrenia, and in some cases, bipolar disorders; they are also used off-label 
for symptoms such as agitation, anxiety, psychotic episodes, and obsessive 
behaviours, as well as in children and the elderly. The findings was done on a 
recent meta-analysis of 150 double-blind, randomized controlled trials (N = 
21,533) raised questions about the notion that atypical antipsychotic as a class 
are truly superior to typical antipsychotic in terms of efficacy and side-effects.  
It was concluded that he older agents have been associated with adverse effects 
such as extra pyramidal symptoms, severe movement disorders, and sudden 
cardiac death, among others55.   
 Kung W. (2015) conducted study was conducted on extra pyramidal side 
effects such as Dystonias, Parkinsonism, and Akathisia. Dystonias are 
prolonged and unintentional muscular contractions of voluntary or involuntary 
muscles. Neuroleptic-induced Parkinsonism is characterized by the triad of 
tremor, rigidity, and bradykinesia; Akathisia is characterized by a patient's 
subjective sense of restlessness, along with such objective evidence of 
restlessness as pacing or rocking. Extra pyramidal side effects were done on 
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random sampling of about 100 patients receiving antipsychotics. 40% of them 
reported with dystonia and manifested, albeit laryngeal dystonia or dystonias of 
other musculature related to breathing. 30% manifested with severe muscular 
rigidity, fever, an altered level of consciousness, and autonomic instability 
characterize neuroleptic malignant syndrome. 20% of them reported with 
akathesia and 10% with Tardive dyskinesia56.  
 Anvar Sadath, D. Muralidhar, Shivarama Varambally, Justin P. 
Jose, and B. N. Gangadhar (2015) Family interventions have produced 
benefits on clinical and family outcomes in long standing psychosis. However, 
little is known about the efficacy of such interventions in the early stages of 
psychosis. This article reviews published research over the last two decades on 
family intervention in first-episode psychosis. Electronic databases, such as 
Pub Med, Psyc INFO, and Science Direct, have been systematically searched. 
In addition, an exhaustive Internet search was also carried out using Google 
and Google Scholar to identify the potential studies that evaluated family 
interventions in first-episode psychosis. We have identified seven reports of 
five randomized controlled trials (RCTs) and five non-randomized and 
uncontrolled studies of family intervention. Our review on 12 reports of family 
intervention studies has shown mixed effects on outcomes in first-episode 
psychosis. Most of the reports showed no added benefits or very short-term 
benefits on primary clinical or family outcome variables. There is a dearth of 
family intervention studies in first-episode psychosis. More RCTs are needed 
to reach reliable conclusions57. 
Astrid M van Strien, Carolina JPW Keijsers, Hieronymus J Derijks, 
Rob J van Marum (2015) investigated on rating scales to measure side effects 
of antipsychotic medication: A systematic review In total, 52 different scales 
were used in the 440 articles retrieved. For multiple side effects measured with 
one scale, the Udvalg for Kliniske Under søgelser Side Effects Rating Scale for 
Clinicians was used the most, whereas the Liverpool University Neuroleptic 
Side Effect Rating Scale had the best psychometric characteristics (Cronbach’s 
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α 0.81 and test–retest reliability 0.89). The Simpson Angus Scale was used the 
most to rate extra pyramidal side effects, although the Maryland Psychiatric 
Research Centre scale had the best characteristics (Cronbach’s α 0.80, test–
retest reliability 0.92 and inter-rater reliability 0.81–0.90). The Arizona Sexual 
Experience Scale was used the most to assess sexual dysfunction, but the 
Antipsychotics and Sexual Functioning Questionnaire and the Nagoya Sexual 
Functioning Questionnaire had the best characteristics58 
             Nicholas J. K. Breitbordel*, Emily K. Bell, David Dawley (2015) 
study is to present clinical and cost outcome data with regard to a first-episode 
psychosis treatment centre within the American mental health system: the Early 
Psychosis Intervention Centre (EPICENTER).Methods: Sixty-eight 
consecutively enrolled individuals with first-episode psychosis completed 
assessments of symptomatology, social functioning, educational/vocational 
functioning, cognitive functioning, substance use, and service utilization upon 
enrolment in EPICENTER and after 6 months of EPICENTER care. All 
participants were provided with access to a multi-component treatment package 
comprised of cognitive behavioural therapy, family psycho education, and 
Meta cognitive remediation. It reveals that over the first 6 months of 
EPICENTER care, participants experienced improvements in symptomatology, 
social functioning, educational/vocational functioning, cognitive functioning, 
and substance abuse. The average cost of care during the first 6 months of 
EPICENTER participation was lower than the average cost during the 6-
months prior to joining EPICENTER. These savings occurred despite the 
additional costs associated with the receipt of EPICENTER care and were 
driven primarily by reductions in the utilization of inpatient psychiatric services 
and contacts with the legal system59. 
                Nevena Divac, Milica Prostran, Igor Jakovcevski, and Natasa 
Cerovac (2014) Numerous studies have examined the incidence and severity of 
extra pyramidal syndrome with first- and second-generation antipsychotics. 
The majority of these studies clearly indicate that extra pyramidal syndrome 
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does occur with second-generation agents, though in lower rates in comparison 
with first generation. Risk factors are the choice of a particular second-
generation agent (with Clozapine carrying the lowest risk and Risperidone the 
highest), high doses, history of previous extra pyramidal symptoms, and co-
morbidity. Also, in comparative studies, the choice of a first-generation 
comparator significantly influences the results. Extra pyramidal syndrome 
remains clinically important even in the era of second-generation 
antipsychotics. The incidence and severity of extra pyramidal syndrome differ 
amongst these antipsychotics, but the fact is that these drugs have not lived up 
to the expectation regarding their tolerability60. 
              Dr. Avinash De Sousa (2013) examined a cohort of patients of first 
episode schizophrenia, in a ten-year follow up study, for the presence of EPS. 
We assessed patients who had shown clinical recovery at the end of ten years 
of treatment. These patients were assessed for psychopathology using the 
PANSS, level of functioning by GAF, cognition by WMS and presence of EPS 
by AIMS. The present study show that abnormal EPS in first episode 
schizophrenia is present in 5% of patients at baseline, and 35.4% after 10 ten 
years. Patients in both groups of normal EPS and abnormal EPS showed equal 
clinical recovery on all parameters. Patients’ EPS symptoms at end point did 
not show any correlation with any end point clinical, social and cognitive 
parameters. We conclude that there is low incidence of EPS in the early phase 
of schizophrenia; however, EPS occur in about a third of all the patients after 
long term ten years treatment. EPS is not found to be correlated to level of 
psychopathology, and it does not correlate with any of the clinical and social 
outcome parameters61 
              Julio Armijo, Emmanuel Méndez, Ricardo Morales, Sara 
Schilling, Ariel Castro, Rubén Alvarado (2013) conducted a compiles and 
synthesizes available scientific evidence from the last 14 years on the 
effectiveness of community intervention strategies for schizophrenia and 
related psychotic disorders. Sixty-six articles were reviewed. Community 
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strategies for integrated treatment from the first outbreak of schizophrenia 
significantly reduced negative and psychotic symptoms, days of 
hospitalization, and co morbidity with substance abuse and improved global 
functioning and adherence to treatment. In other stages, there were improved 
outcomes in negative and positive symptoms and general psychopathology. 
Psycho education for patients and families reduced the levels of self-stigma and 
domestic abuse, as well as improved knowledge of the disease and treatment 
adherence. Training focused on cognitive, social, and labour skills has been 
shown to improve yields in social functioning and employment status62. 
               Peter M Haddad, Amlan Das, Sarvenaz Keyhaniand Imran B 
Chaudhry (2012) determined whether the risk of extra pyramidal side effects 
(EPS) differed between antipsychotic drugs used in first episode psychosis 
(FEP). We identified 11 RCTs comparing two or more antipsychotics in FEP 
and reporting on EPS. All trials assessed one or more second generation 
antipsychotics (SGAs), one assessed chlorpromazine, one zuclopenthixol and 
seven trials assessed haloperidol. Assessment and reporting of EPS varied. 
Compared with one or more SGA comparators, haloperidol was associated 
with significantly higher rates/severity of parkinsonism (seven trials) and 
Akathisia (six trials) and greater use of anti cholinergics (five trials) and beta-
blockers (two trials). Two trials with low-dose haloperidol (≤ 4 mg) showed 
significantly worse EPS outcomes versus a SGA. Two of four long-term 
haloperidol trials (≥ 1 year) found a higher Dyskinesia-risk with haloperidol 
versus Olanzapine and Risperidone respectively; the remaining two trials found 
no difference (various SGA comparators). There was an EPS advantage for 
Clozapine versus chlorpromazine (one trial) and Risperidone versus 
Zuclopenthixol (one trial). There was little evidence of EPS-differences 
between SGAs, possibly reflecting use of low doses63. 
             René S Kahn*, W Wolfgang Fleisch hacker*, Han Boter, Michael 
Davidson (2008) investigated on open randomised controlled trial of 
haloperidol versus second-generation antipsychotic drugs in 50 sites, in 14 
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countries. Eligible patients were aged 18–40 years, and met diagnostic criteria 
for schizophrenia, schizophrenic form disorder, or schizoaffective disorder. 498 
patients were randomly assigned by a web-based online system to haloperidol 
(1–4 mg per day; n=103), Amisulpride (200–800 mg per day; n=104), 
Olanzapine (5–20 mg per day; n=105), Quetiapine (200–750 mg per day; 
n=104), or Ziprasidone (40–160 mg per day; n=82); follow-up was at 1 year. 
The primary outcome measure was all-cause treatment discontinuation. 
Patients and their treating physicians were not blinded to the assigned 
treatment64. 
                 Chouinard G, Margolese HC.(2005) The Extra pyramidal 
Symptom Rating Scale (ESRS) was developed to assess four types of drug-
induced movement disorders (DIMD): Parkinsonism, Akathisia, Dystonia, and 
Tardive Dyskinesia (TD). Comprehensive ESRS definitions and basic 
instructions are given. Factor analysis provided six ESRS factors: 1) 
Hypokinetic Parkinsonism; 2) Orofacial Dyskinesia; 3) trunk/limb Dyskinesia; 
4) Akathisia; 5) tremor; and 6) Tardive Dystonia. Two pivotal studies found 
high inter-rater reliability correlations in both antipsychotic-induced movement 
disorders and idiopathic Parkinson disease. For inter-rater reliability and 
certification of raters, >or=80% of item ratings of the complete scale should be 
+/-1 point of expert ratings and >or=70% of ratings on individual items of each 
ESRS subscale should be +/-1 point of expert ratings. During a cross-scale 
comparison, AIMS and ESRS were found to have a 96% (359/374) agreement 
between TD-defined cases by DSM-IV TD criteria. Two recent international 
studies using the ESRS included over 3000 patients worldwide and showed an 
incidence of TD ranging from 10.2% (2000) to 12% (1998). ESRS specificity 
was investigated through two different approaches, path analyses and 
ANCOVA PANSS factors changes, which found that ESRS measurement of 
drug-induced EPS is valid and discriminative from psychiatric symptoms65. 
D.N.Mendhekar, R.C.Jiloha, M.M.Mehndiratta & L.War (2002) 
investigated several reports available on neuroleptic malignant syndrome 
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(NMS) associated with risperidone but when a more stringent criterion is 
applied there are only a few. Report on challenge and re-challenge with various 
atypical antipsychotic drugs in re-emergence of post NMS psychosis is scanty. 
Our aim of presenting this is to highlight the differential response of various 
atypical antipsychotic drugs in the treatment of post NMS psychosis. This 
paper reports a young male with mild mental retardation who developed NMS 
on a low dose of nspendone. Earlier he was on haloperidol 10 mg. which was 
stopped 10 days prior to initiation of risperidone therapy. Symptoms of NMS 
resolved within 36 hours with bromocnptine; but the patient relapsed to 
psychosis. Re-challenge with risperidone 1mg resulted in a dystonic reaction, 
with clozapine 12.5 mg he developed marked sedation, hypotension and 
urinary incontinence. Ultimately post NMS psychosis responded well to 
olanzapine 10 mg and there was no recurrence of NMS. Olanzapine may be the 
better choice for the treatment of post NMS psychosis66. 
2.2 CONCEPTUAL FRAME WORK 
 Modified Orlando’s Theory of Deliberative Nursing Process (1990) 
              Orlando was one of the earliest nurse theorist and one of the first 
people to develop nursing inductively from the empirical study of   nursing 
practice. Orlando’s theory has radically shifted   the nurse’s focus from medical 
diagnosis, to the nursing diagnosis that is finding and meeting the client’s 
immediate needs. 
 Orlando’s nursing process is composed of the following basic elements 
1. Care givers(client’s) behaviour 
2. Reaction of the nurse 
3. The  Nursing activities  which are designed for  the clients  distress 
Orlando says that nurses should help in relieving the physical and mental 
discomfort and should not add to the client’s distress. 
In this theory, nursing process is used by nurses to meet the care givers 
(clients) needs. Meeting the needs improves the anti psychotics drugs 
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consuming people behaviour. The behaviour may be problems in speaking, 
memory, making decisions, fluctuations in mood, loss of interest in hobbies 
and activities.  
Nurse reacts to the client’s behaviour and act accordingly. After 
completion, the nursing action is evaluated for its effectiveness. 
  Patient(caregivers of patients on antipsychotic drugs) Behaviour   
 Care givers have inadequate knowledge in identifying extra pyramidal 
symptoms, which are side effects of anti psychotics.  
Nurse Reaction  
           Nurse perceives the care givers of patients on antipsychotics behaviour 
(demographic variable) and feels that the care givers has some needs to be met 
validating the same by communicating   with the client. The nurse investigator 
assesses the pre assessment level and post assessment level of knowledge by 
modified standard questionnaire. 
 Nurse Action  
Deliberative nurse actions involving exploring the meaning and identify 
the extra pyramidal symptoms among the care givers of patients on anti 
psychotics and actions are evaluated for effectiveness after completion (post 
test). 
           In deliberative nurse actions involves exploring the meaning (verifying) 
and identifying the need of the care givers. The nurse investigator’s activity is 
in planning and implementing the nursing action for meeting the care givers 
needs or improving the care givers behaviour (improve knowledge on extra 
pyramidal symptoms). Here the nurse action is applying psycho education on 
identification of extra pyramidal symptoms for 7 days period of time. After that 
post assessment was done to find out effectiveness of nurse action. If there is 
marked improvement in knowledge advise them to give adequate care to the 
clients who receiving anti psychotics, or reduction in knowledge go back for 
further process.  
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CHAPTER-III 
METHODOLOGY 
This chapter explains the methodology in detail. It includes research 
design, setting of the study, sampling technique, tools, pilot study, data 
collection process and plan for the data analysis. The study was conducted to 
assess the effectiveness of psycho education module on improving knowledge 
regarding extra pyramidal symptoms among caregivers of patients on 
antipsychotic drugs attending outpatient department at IMH, Chennai. 
3.1   Research approach  
Quantitative approach. 
3.2   Research Design:    Pre experimental, one group pre test post test 
research design without control group and randomization. 
Key words: 
01=Pre-test knowledge of extra pyramidal symptoms among caregivers of 
patients receiving antipsychotics. 
X= Psycho education module on knowledge regarding extra pyramidal 
symptoms. 
02= Post-test knowledge of extra pyramidal symptoms among caregivers of 
patients receiving antipsychotics. 
 
Group Pre-test Intervention Post-test 
Caregivers of patients receiving 
antipsychotics attending the OPD 
at IMH, Chennai 
01 X 02 
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DATA COLLECTION PERIOD:  
The study was conducted for four weeks from 02.01.2018 to 29.01.2018 
DESCRIPTION OF VARIABLE: 
INDEPENDENT VARIABLE:  
Psycho education module on knowledge regarding extra pyramidal 
symptoms by anti psychotics. 
DEPENDENT VARIABLE: 
 Knowledge of extra pyramidal symptoms among caregivers of patients 
receiving antipsychotics 
3.3 Study setting 
      This study was conducted in Psychiatric outpatient department at 
Institute of Mental Health, Chennai. Institute of Mental Health is involved in 
Mental Health care for the past 206 Years. Founded in 1794 as an asylum to 
manage 20 patients, it has grown into an Institute with bed strength of 1800 
patients. Special service like rehabilitation service, industrial therapy, 
occupational therapy, recreational therapy, family therapy, yoga, etc are 
available in this institution and are given separately for male and female 
patients, hospital runs OPD ( outpatient department) under 6 units by the 
eminent psychiatrist and on average 580-600 patients receive mental health 
outpatient service per day. 
3.4 Study Population: 
 Target population:  
  Caregivers of patients attending OPD, IMH at Chennai. 
Accessible population  
Caregivers of patients receiving  antipsychotics in attending OPD, IMH 
at Chennai. 
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3.5   Sample:Care givers of anti psychotic drugs. 
3.6   Sample size: 60.         
3.7   Sampling technique:  Convenient sampling technique. 
3.8 Research variables: 
Independent Variable - Psycho Education Module   
Dependent Variable - Knowledge Regarding EPS among Caregivers 
3.9 Criteria for sample selection:- 
3.9.1. (a)   Inclusion Criteria:  
1. Caregivers who are willing to participate in the study. 
2. Both male and female who are willing to participate in the study. 
Caregivers who are able to read and write Tamil and English. 
3.9.1. (b)   Exclusion Criteria:- 
1. care givers Who are not available during my data collection. 
2.Caregivers who are all not able to followup regularly. 
     Development and Description of the tool 
  Development of Tool: 
Tool was selected after extensive literature review from the various text 
book, internet search, guidance and discussion with experts in the field of 
nursing, psychiatry and statistics. A structured questionnaire was used to 
collect data from the caregivers regarding extra pyramidal symptoms who were 
attending OPD in Institute of mental health, Chennai. 
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3.10   Tool For Data Collection  
The tool consists of Section A and B. It  is divided into two parts. 
3.10.1 Part-A:  
Demographic data which consists of age, sex, marital status, education. 
3.10.2 Part-B:  
MGASS will be used to assess the level of knowledge of caregivers 
regarding extra pyramidal symptoms and after administering MGASS 
description programme after 7 days, post test knowledge will be assessed.  
3.11    Content Validity 
Data collection tool is an instrument that measures the variables of 
interest of the study accurately, precisely and sensitively. Content validity of 
the tool was obtained from experts in the field of psychiatric nursing, 
psychiatry, psychology and statistical expert. The experts were an associate 
professor, psychiatrist and clinical psychologist. The experts were requested to 
check the relevance, sequence and adequacy of the content. There was uniform 
agreement of the tool which is adopted to conduct the study. Hence, the 
investigator precedes the same tool. 
3.12  Ethical Consideration 
The study objectives, intervention, data collection procedure approved 
by the Ethical Committee of Madras Medical College, Chennai. The caregivers 
regarding extra pyramidal symptoms were explained about the purpose and 
need for the study. They were assured that their details and answers will be 
used only for the research purpose. Further they were ensured that their details 
will be kept confidentially. Thus the investigator followed the ethical 
guidelines, which were issued by the Ethical Committee after getting a written 
permission. 
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3.13.    Pilot Study 
Pilot study is a trail run for the main study to test the reliability, 
practicability and feasibility of the study. The main objectives of the pilot study 
are to help the researcher to become familiar with the use of tool and to find out 
the difficulties in the main study. The pilot study was conducted after getting 
ethical clearance and the permission from the Institute of mental health, 
Chennai. It was conducted for a period of one week from. Sample of 10 
caregivers regarding extra pyramidal symptoms were selected by convenient 
sampling technique. Informed consent was obtained from them before 
collection of the data. Data were collected from the caregivers regarding extra 
pyramidal symptoms by structured questionnaire before the implementation of 
psycho education. After completion of psycho education sessions, the 
caregivers regarding extra pyramidal symptoms were assessed their clients 
symptoms of EPS by using same scale. Pilot study samples are excluded in the 
main study. 
3.14      Reliability of the Tool 
After pilot study reliability of the tool was assessed by using split - half 
method. The ‘r’ value obtained was 0.85 which showed a high positive 
correlation. Hence the tool was considered reliable. 
3.15   METHOD OF DATA COLLECTION: 
Setting of the study: 
The study will be conducted in OPD, in IMH, Chennai. It is a 1800 
bedded hospital which is located at 7km distance away from College of 
Nursing. Prior to data collection, permission will be obtained from the 
concerned authority. After obtaining the consent the investigator will explain 
the purpose of the study to the subjects by structured interview schedule and 
structured knowledge questionnaire will be administered, followed by a psycho 
education module and post test will be assessed after 2 weeks.  
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The entire data collection procedure was spread out over a period of four 
weeks from 02-01-2018 to 29-01-2018.There are daily 200-300 male and 
female caregivers of age group from 20 to 50 years, irrespective of caste, creed 
and religion. Initially the investigator approaches each female clients after 
getting permission from the Director.  
Investigator selected 70 care givers initially. In that 2 of them were 
dropped due to chronic illness, 3 of them were unable to attend due to their 
physical inability and 5 were not willing to participate in the study. The 
investigator selected 60 care givers as per the inclusion and exclusion criteria. 
The care givers were introduced with the whole programme after an 
introduction and then a written informed consent was obtained from them for 
willingness to participate in the study. They were assured that their responses 
and details will be kept confidential and will be used only for the research 
purpose. Before the tool was administered some informal discussion were 
made with participants to establish rapport so that they would be relaxed.  
3.16    Intervention Protocol 
The total 60 male and female care givers were divided into two groups. 
Each group contained 30 people. Every day the participants were gathered 
around 7AM  in the common hall. In the first two days  pre test questionnaire 
was administered to them and they were asked to give appropriate answers for 
all statements to find out the  level of knowledge regarding EPS by MGASS 
description Marks Value.  Following assessment two weeks of psycho 
education on care of EPS, Before starting psycho education the researcher were 
introduced herself to the care givers and asked the care givers to introduce 
themselves. Every day psycho education started with morning session from 8 
a.m. to 10 a. m. After the psycho education post test was done by modified 
Glascow Antipsychotics side effect scale to assess the knowledge level of 
caregivers.    
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3.17 Data entry and Data Analysis:- 
The data obtained will be analyzed in terms of objectives of the study using 
descriptive and inferential statistics. 
1)  Descriptive statistics: 
• Frequency and percentage distribution will be used to analyze the 
demographic variables of caregivers. 
• Mean and standard deviation will be used to analyze the level of 
knowledge among caregivers. 
2)  Inferential statistics:- 
• Paired’t’ test will be used to find out the significant difference between 
the mean pretest and post test knowledge score of caregivers.   
• Chi square test will be used to find out the level of knowledge with 
selected demographic variables. 
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CHAPTER IV 
DATA ANALYSIS AND INTERPRETATION 
This chapter deals with analysis and interpretation of the collected data 
from 60 caregivers of patients on antipsychotic drugs attending outpatient 
department at IMH, Chennai. The purpose of the analysis is to convert the 
collected data to an interpreted meaningful form,so that the results can be 
found and association can be identified.Statistical analysis helps the researcher 
to make sense of quantitative information. Statistical procedure enables the 
researcher to summarize,organize,evaluate,interpret&communicate numeric 
information. 
 The collected data were tabulated and presented according to the 
objectives under the following headings 
 Section I:  
Deals with the socio demographic variables 
 Section II: 
Assess the pretest knowledge of caregiver regarding extra pyramidal 
symptoms. 
 Section III: 
Assess the posttest knowledge of caregiver regarding extra pyramidal 
symptoms. 
 Section IV:  
Assess the effectiveness of psycho education module. 
 Section V: 
Association between posttest knowledge score and selected 
demographic variables. 
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Section I: Table 4.1 - Socio demographic variables of care givers. 
Demographic variables 
No. of 
caregivers 
% 
Age 
21 -30 years 38 63.3% 
31 -40 years 13 21.7% 
41 -50 years 6 10.0% 
51 -60 years 3 5.0% 
Sex 
Male 40 66.7% 
Female 20 33.3% 
Living area 
Rural 35 58.3% 
Urban 20 33.4% 
Semi urban 5 8.3% 
Marital status 
Married 36 60.0% 
Unmarried 19 31.7% 
Widow 5 8.3% 
Others 0 0.0% 
Occupation status 
Cooly 30 50.0% 
Business 22 36.6% 
State government 7 11.7% 
Central government 1 1.7% 
Type of Family 
Joint family 19 31.6% 
Nuclear family 31 51.7% 
Extended family 10 16.7% 
Income of the 
family 
Rs 5001- 10,000 30 50.0% 
Rs 10,001- 20,000 18 30.0% 
Rs 20,001- 30,000 6 10.0% 
>Rs 30,000 6 10.0% 
Years of getting 
treatment for 
1- 5 years 24 40.0% 
6 -10 years 21 35.0% 
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psychosis 11- 15 years 10 16.7% 
> 15 years 5 8.3% 
Side effects of 
antipsychotics are 
Drawling of saliva 21 35.0% 
Rigidity of body and 
neck 
26 43.3% 
Eye balls moves up 10 16.7% 
Fever with palpitation 3 5.0% 
EPS means 
Extra psychiatric 
symptoms 
26 43.3% 
Extra pyramidal 
symptoms 
21 35.0% 
Extra pyramidal 
syndrome 
9 15.0% 
Extra six symptoms 4 6.7% 
Treatment measure 
for EPS is 
Getting treatment in 
psychiatric OPD 
30 50.0% 
Getting local traditional 
treatment 
18 30.0% 
Getting black magic 
treatment 
6 10.0% 
Stop to attending 
psychiatric OPD 
6 10.0% 
The above table 4.1 shows the demographic information of care givers 
those who are participated for the following study on “Assess the effectiveness 
of psycho education module on knowledge regarding extra pyramidal 
symptoms among caregivers of patients on antipsychotic drugs attending 
outpatient department at IMH, Chennai”. 
 Among 60 caregivers (63.3%) were 21-30 years, (21.7%) were 31-40 
years, (10%) were 41-50 years, (5%) were 51-60 years. 
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 In case of sex (66.7%) were males, (33.3%) were females. 
 According to living area (58.3%) were from rural, (33.4%) were from 
urban, (8.3%) were from semi urban. 
 In marital status (60%) were married, (31.7%) were unmarried, (8.3%) 
were widow, and none of them in other categories. 
 According to occupation status (50%) were cooly, (36.6%) were doing 
business, (11.7%) were state government employee, (1.7%) were central 
government employee. 
 The type of family revealed that (51.7%) were nuclear family, (31.6%) 
were joint family, and (16.7%) were extended family. 
 Regarding income of the family (50%) were earned Rs. 5001-10,000, 
(30%) were earned Rs. 10,001-20,000, (10%) Rs. 20,001-30,000, (10%) were 
earned more than 30,000. 
 According to years of getting treatment for psychosis (40%) were 1-5 
years, (35%) were 6-10 years, (16.7%) were 11-15 years and (8.3%) were more 
than 15 years. 
 Knowledge regarding side effects of antipsychotics was (43.3%) thought 
rigidity of body and neck, (35%) thought drawling of saliva, (16.7%) thought 
eye balls moves up, (5%) thought fever with palpitation. 
 Caregiver knowledge about EPS means was (43.3%) were thought extra 
psychiatric symptoms, (35%) were thought extra pyramidal, (15%) were extra 
pyramidal syndrome, (6.7%) were thought extra six symptoms. 
 Caregiver knowledge about treatment measure for EPS is (50%) were 
thought getting treatment in psychiatric OPD, (30%) were thought getting local 
traditional treatment, (10%) getting black magic treatment, (10%) were thought 
stop to attending psychiatric OPD.  
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Section II: Assess the pretest knowledge of caregiver regarding extra 
pyramidal symptoms. 
Table 2: Each question wise pretest level of knowledge score 
S.No. Questions 
Never Once 
A few 
times 
Every
day 
0 1 2 3 
1 Is your relative felt sleepy during the day 0 40 18 2 
2 Is your relative felt drugged or like a zombie 0 39 20 1 
3 
Is your relative felt dizzy when they stood up 
and/or have fainted 
0 35 23 2 
4 
Is your relative  felt  heart beating irregularly or 
unusually fast 
1 24 32 3 
5 Is your relative muscles have been tense or jerky 2 23 30 5 
6 Is your relative hands or arms have been shaky 2 24 25 9 
7 
Is your relative legs have felt restless and/or they 
couldn’t sit still 
6 31 15 8 
8 Is your relative  have been drooling 0 30 18 12 
9 
Is your relative movements or walking have 
been slower than usual 
1 31 20 8 
10 
Is your relative have had, or people have noticed 
uncontrollable movements of their face or body 
2 28 26 4 
11 Is your relative vision has been blurry 8 26 20 6 
12 Is your relative mouth has been dry 4 35 19 2 
13 Is your relative have had difficulty passing urine 2 31 21 6 
14 
Is your relative  have felt like they going to be 
sick or have vomited 
4 35 15 6 
15 Is your relative have wet the bed 7 24 24 5 
16 
Is your relative have been very thirsty and/or 
passing urine frequently 
2 31 22 5 
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17 
The areas around their nipples have been sore 
and wollen 
9 28 17 6 
18 
Is your relative have noticed fluid coming from 
my nipples 
13 28 14 5 
19 Is your relative  have had problems enjoying sex 16 22 17 5 
20 
Men only:  have had problems getting an 
erection 
33 12 10 5 
21 
Women only: Is your relative  have noticed a 
change in their periods 
45 0 0 15 
22 
Men and women: Is your relative have been 
gaining weight 
40 0 0 20 
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Table 4.3: Each question wise pretest percentage of knowledge score of 
care giver regarding extra pyramidal symptoms 
S.No. Questions 
M
a
x
im
u
m
 
sc
o
re
 
M
ea
n
 
sc
o
re
 
SD
 
%
 
o
f m
ea
n
 
sc
o
re
 
1 Is your relative felt sleepy during the day 3 1.37 .55 45.67% 
2 Is your relative felt drugged or like a 
zombie 
3 1.37 .52 45.67% 
3 Is your relative felt dizzy when they stood 
up and/or have fainted 
3 1.45 .57 48.33% 
4 Is your relative  have felt their heart 
beating irregularly or unusually fast 
3 1.62 .61 54.00% 
5 Is your relative muscles have been tense or 
jerky 
3 1.63 .69 54.33% 
6 Is your relative hands or arms have been 
shaky 
3 1.68 .77 56.00% 
7 Is your relative legs have felt restless 
and/or they couldn’t sit still 
3 1.42 .85 47.33% 
8 Is your relative have been drooling 3 1.70 .79 56.67% 
9 Is your relative movements or walking 
have been slower than usual 
3 1.58 .74 52.67% 
10 Is your relative have had, or people have 
noticed uncontrollable movements of my 
face or body 
3 
1.53 .68 
51.00% 
11 Is your relative vision has been blurry 3 1.40 .85 46.67% 
12 Is your relative mouth has been dry 3 1.32 .65 44.00% 
58 
 
13 Is you relative have had difficulty passing 
urine 
3 1.52 .72 50.67% 
14 Is your relative  have felt like  going to be 
sick or have vomited 
3 1.38 .76 46.00% 
15 Is your relative have wet the bed 3 1.45 .81 48.33% 
16 Is your relative have been very thirsty 
and/or passing urine frequently 
3 1.50 .70 50.00% 
17 The areas around their nipples have been 
sore and swollen 
3 1.33 .86 44.33% 
18 Is your relative have noticed fluid coming 
from their nipples 
3 1.18 .87 39.33% 
19 Is your relative have had problems 
enjoying sex 
3 1.18 .93 39.33% 
20 Men only: Is your relative have had 
problems getting an erection 
3 
.78 1.01 26.00% 
21 Women only: Is your relative have noticed 
a change in their periods 
3 
.75 1.31 25.00% 
22 Men and women: Is your relative have 
been gaining weight 
3 1.00 1.43 33.33% 
 Overall 66 30.15 4.68 45.68% 
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Table 4.4:    Pretest level of knowledge score 
Level of 
knowledge 
No. of 
caregivers 
% 
Good 0 0.0% 
Moderate 16 26.7% 
Poor 44 73.3% 
Total 60 100% 
The above table 4.4 shows the pretest level of knowledge score 
regarding extra pyramidal symptoms among caregivers of patients on 
antipsychotic drugs Using Glasgow Antipsychotic Side-effect Scale (GASS). 
In general, none of the caregivers are having good level knowledge 
score, 26.7% are having Moderate level knowledge score and 73.3% of them 
having poor level of knowledge score on extra pyramidal symptoms 
GASS score interpretation: 
0 – never 1-Once 2 – few times 3 - everyday 
Min=0 Max=3 Total questions=22 Maximum marks= 66 
S No.  Grade  Score 
1. Good 0 – 12 
2. Moderate  13 – 26 
3. Poor >26 
Scoring patters 
1. Allow the patient to fill in the questionnaire themselves.  
Questions 1‐20 relate to the previous week and questions 21‐22 to the last three 
months.  
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2. Scoring For questions 1‐20 award 1 point for the answer “once”, 2 points 
for the answer “a few times” and 3 points for the answer “everyday”. Please 
note zero points are awarded for an answer of “never”.   
 For questions 21 and 22 award 3 points for a “yes” answer and 0 points for a 
“no”. Total for all questions= 3.  
For male and female patients a total score of:   0‐12 = absent/mild side effects 
13‐26 = moderate side effects   over 26 = severe side effects 
Section III: Assess the posttest knowledge of caregiver regarding extra 
pyramidal symptoms. 
Table 4.5: Each question wise posttest level of knowledge score 
S.No. Questions 
Never Once 
A few 
times 
Every 
day 
0 1 2 3 
1 Is your relative felt sleepy during the day 14 42 4 0 
2 
Is your relative felt drugged or like a 
zombie 
14 42 4 0 
3 
Is your relative felt dizzy when they 
stood up and/or have fainted 
27 33 0 0 
4 
Is your relative have felt their heart 
beating irregularly or unusually fast 
30 29 1 0 
5 
Is your relative muscles have been tense 
or jerky 42 15 3 0 
6 
Is your relative hands or arms have been 
shaky 
39 20 1 0 
7 
Is your relative legs have felt restless 
and/or they couldn’t sit still 
37 22 1 0 
8 Is your relative have been drooling 38 19 3 0 
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9 
Is your relative movements or walking 
have been slower than usual 
32 25 3 0 
10 
Is your relative have had, or people have 
noticed uncontrollable movements of 
their face or body 
30 27 3 0 
11 Is your relative  vision has been blurry 25 33 2 0 
12 Is your relative mouth has been dry 27 31 2 0 
13 
Is your relative have had difficulty 
passing urine 
29 29 2 0 
14 
Is your relative have felt like  going to 
be sick or have vomited 
28 32 0 0 
15 Is your relative have wet the bed 24 35 1 0 
16 
Is your relative have been very thirsty 
and/or passing urine frequently 
26 33 1 0 
17 
The areas around their  nipples have 
been sore and woollen 
25 32 3 0 
18 
Is your relative have noticed fluid 
coming from their nipples 
21 37 2 0 
19 
Is your relative  have had problems 
enjoying sex 17 42 1 0 
20 
Men only: Is your relative  have had 
problems getting an erection 
27 33 0 0 
21 
Women only: Is your relative have 
noticed a change in they periods 
57 3 0 0 
22 
Men and women: Is your relative have 
been gaining weight 
59 1 0 0 
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Table 4.6:   Each question wise posttest percentage of knowledge score 
S.No. Questions 
M
a
x
im
u
m
 
sc
o
re
 
M
ea
n
 
sc
o
re
 
SD
 
%
 
o
f m
ea
n
 
sc
o
re
 
1 Is your relative felt sleepy during the day 3 .93 .45 31.00% 
2 Is your relative felt drugged or like a zombie 3 .93 .45 31.00% 
3 I felt dizzy when they stood up and/or have fainted 3 .65 .48 
21.67% 
4 Is your relative have felt their heart beating irregularly or unusually fast 3 .62 .52 
20.67% 
5 Is your relative muscles have been tense or jerky 3 .45 .59 15.00% 
6 Is your relative hands or arms have been 
shaky 3 .47 .54 
15.67% 
7 Is your relative legs have felt restless and/or 
they couldn’t sit still 3 .50 .54 
16.67% 
8 Is your relative have been drooling 3 .52 .60 17.33% 
9 Is your relative movements or walking have been slower than usual 3 .62 .58 
20.67% 
10 
Is your relative have had, or people have 
noticed uncontrollable movements of their 
face or body 
3 .65 .58 21.67% 
11 Is your relative vision has been blurry 3 .72 .52 24.00% 
12 Is your relative mouth has been dry 3 .68 .54 22.67% 
13 Is your relative have had difficulty passing 
urine 3 .65 .55 
21.67% 
14 Is your relative have felt like  going to be sick 
or have vomited 3 .63 .49 
21.00% 
15 Is your relative have wet the bed 3 .72 .49 24.00% 
16 Is your relative  have been very thirsty and/or passing urine frequently 3 .67 .51 
22.33% 
17 The areas around their nipples have been sore 
and wollen 3 .73 .55 
24.33% 
18 Is your relatives have noticed fluid coming from their nipples 3 .77 .50 
25.67% 
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19 Is your relative  have had problems enjoying 
sex 
3 .82 .43 27.33% 
20 Men only: Is your relative  have had problems getting an erection 3 .65 .48 
21.67% 
21 Women only: Is your relative  have noticed a 
change in their periods 3 .15 .36 
5.00% 
22 Men and women: Is your relative have been gaining weight 3 .12 .32 
4.00% 
 Overall 66 13.63 2.96 20.65% 
Table 4.7: Posttest level of knowledge score 
Level of knowledge No. of 
caregivers 
% 
Good 23 38.3% 
Moderate  37 61.7% 
Poor 0 0.0% 
           Total 60 100% 
The above table 4.7 shows the   posttest level of knowledge score 
regarding extra pyramidal symptoms among caregivers of patients on 
antipsychotic drugs Using Glasgow Antipsychotic Side-effect Scale (GASS). 
In general 38.3% of the caregivers are having good level knowledge 
score,  61.7% are having Moderate level knowledge score and  none of them 
having poor  level of knowledge score on pyramidal symptoms. 
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Section IV: Assess the effectiveness of psycho education module. 
Table 4.8:  Comparison of pretest and posttest knowledge score 
  
S. 
No. 
Knowledge on 
Pretest Posttest Mean 
Differ
ence 
Student’s 
paired 
t-test 
Mean SD Mean SD 
1 
Is your relative felt 
sleepy during the 
day 
1.37 .55 .93 .45 0.44 
t=4.65P=0.001 
*** 
DF= 59 , 
Significant 
2 
Is your relative felt 
drugged or like a 
zombie 
1.37 .52 .93 .45 0.44 
t=4.81 P=0.001 
*** 
DF= 59 , 
Significant 
3 
Is your relative felt 
dizzy when they 
stood up and/or have 
fainted 
1.45 .57 .65 .48 0.8 
t=9.40 P=0.001 
*** 
DF= 59 , 
Significant 
4 
Is your relative have 
felt their heart 
beating irregularly or 
unusually fast 
1.62 .61 .62 .52 1 
t=9.18 P=0.001 
*** 
DF= 59 , 
Significant 
5 
Is your relative 
muscles have been 
tense or jerky 
1.63 .69 .45 .59 1.18 
t=11.27P=0.00
1 *** 
DF= 59 , 
Significant 
6 
Is your relative 
hands or arms have 
been shaky 
1.68 .77 .47 .54 1.21 
t=10.89 
P=0.001 *** 
DF= 59 , 
Significant 
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7 
Is your relative  legs 
have felt restless 
and/or they couldn’t 
sit still 
1.42 .85 .50 .54 0.92 
t=6.78 P=0.001 
*** 
DF= 59 , 
Significant 
8 
Is your relative have 
been drooling 
1.70 .79 .52 .60 1.18 
t=9.01 P=0.001 
*** 
DF= 59 , 
Significant 
9 
Is your relative  
movements or 
walking have been 
slower than usual 
1.58 .74 .62 .58 0.96 
t=8.88 P=0.001 
*** 
DF= 59 , 
Significant 
10 
Is your relative have 
had, or people have 
noticed 
uncontrollable 
movements of their 
face or body 
1.53 .68 .65 .58 0.88 
t=8.09 P=0.001 
*** 
DF= 59 , 
Significant 
11 
Is your relative 
vision has been 
blurry 
1.40 .85 .72 .52 0.68 
t=5.38 P=0.001 
*** 
DF= 59 , 
Significant 
12 Is your relative 
mouth has been dry 1.32 .65 .68 .54 0.64 
t=6.28 P=0.001 
*** 
DF= 59 , 
Significant 
13 
Is your relative  have 
had difficulty 
passing urine 
1.52 .72 .65 .55 0.87 
t=7.52 P=0.001 
*** 
DF= 59 , 
Significant 
14 
Is your relative have 
felt like going to be 
sick or have vomited 
1.38 .76 .63 .49 0.75 
t=7.12 P=0.001 
*** 
DF= 59 , 
Significant 
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*** Very high significant at   P≤0.001   
The above table 4. 8 shows the comparison of pretest and  posttest 
knowledge score. 
Each question wise there is a statistically significant difference between 
pretest and posttest score.  Significance of difference between pretest and 
posttest score was calculated using student paired t-test.  
15 Is your relative have 
wet the bed 1.45 .81 .72 .49 0.73 
t=6.75 P=0.001 
*** 
DF= 59 , 
Significant 
16 
Is your relative have 
been very thirsty 
and/or passing urine 
frequently 
1.50 .70 .67 .51 0.83 
t=7.81 P=0.001 
*** 
DF= 59 , 
Significant 
17 
The areas around 
their nipples have 
been sore and 
swollen 
1.33 .86 .73 .55 0.6 
t=5.03 P=0.001 
*** 
DF= 59 , 
Significant 
18 
Is your relative  have 
noticed fluid coming 
from their nipples 
1.18 .87 .77 .50 0.41 
t=3.41 P=0.001 
*** 
DF= 59 , 
Significant 
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Table 4.9: comparison of overall knowledge score before and after psycho 
education module 
 No. of 
caregivers 
Pretest 
Mean±S
D 
Posttest 
Mean±S
D 
Meandiff
erence 
Mean±S
D 
Student’S 
paired 
t-test 
Overall  
Score 
60 
30.15 ± 
4.67 
13.63 ± 
2.95 
16.51± 
4.42 
t=28.91 
P=0.001*** 
DF = 59, 
significant 
 
*** Very high significant at   P≤0.001   
The above table 4.9 shows the comparison of overall symptoms 
knowledge before and after the administration of psycho education module. On 
an average, in pre test caregivers are having 30.15score after the administration 
of psycho education module they are having 13.63 knowledge score. 
Difference is 16.51, this difference is statistically significant. Statistical 
significance was calculated by using student’s paired‘t’ test. 
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Table 4.10 Each question wise pretest and posttest percentage of stress 
S.No. Domains 
Pretest 
stress 
Posttest 
stress 
% of 
stress 
reduction 
Score 
1 Is your relative felt sleepy during the day 45.67% 31.00% 14.67% 
2 Is your relative felt drugged or like a 
zombie 45.67% 31.00% 14.67% 
3 Is your relative felt dizzy when they 
stood up and/or have fainted 48.33% 21.67% 26.66% 
4 Is your relative have felt their heart beating irregularly or unusually fast 54.00% 20.67% 33.33% 
5 Is your relative muscles have been 
tense or jerky 54.33% 15.00% 39.33% 
6 Is your relative  hands or arms have been shaky 56.00% 15.67% 40.33% 
7 Is your relative legs have felt restless 
and/or they couldn’t sit still 47.33% 16.67% 30.66% 
8 Is your relative have been drooling 56.67% 17.33% 39.34% 
9 Is your relative movements or walking have been slower than usual 52.67% 20.67% 32.00% 
10 
Is your relative have had, or people 
have noticed uncontrollable 
movements of their face or body 
51.00% 21.67% 29.33% 
11 Is your relative vision has been blurry 46.67% 24.00% 22.67% 
12 Is your relative mouth has been dry 44.00% 22.67% 21.33% 
13 Is your relative  have had difficulty passing urine 50.67% 21.67% 29.00% 
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The above table 4.10 shows each question wise knowledge score among 
caregivers of patients on antipsychotic drugs attending outpatient department at 
IMH, Chennai. 
 
  
 
 
 
14 Is your relative have felt like  going to be sick or have vomited 46.00% 21.00% 25.00% 
15 Is your relative  have wet the bed 48.33% 24.00% 24.33% 
16 Is your relative  have been very thirsty 
and/or passing urine frequently 50.00% 22.33% 27.67% 
17 The areas around their  nipples have been sore and woolen 44.33% 24.33% 20.00% 
18 Is your relative  have noticed fluid 
coming from their  nipples 39.33% 25.67% 13.66% 
19 Is your relative have had problems 
enjoying sex 39.33% 27.33% 12.00% 
20 Men only: Is your relative  have had problems getting an erection 26.00% 21.67% 4.33% 
21 Women only: Is your relative  have 
noticed a change in their  periods 25.00% 5.00% 20.00% 
22 Men and women: Is your relative have been gaining weight 33.33% 4.00% 29.33% 
 Overall 45.68% 20.65% 25.03% 
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Table 4.11:   Comparison of pretest and posttest level of knowledge score 
Level of 
knowledge 
Pretest Posttest Generalized 
McNemar’s 
test n % n % 
Good 0 0.0% 23 38.3% 
χ2=49.22 
P=0.001***(S) 
 
Moderate 
16 26.7% 37 61.7% 
Poor 44 73.3% 0 0.0% 
Total 60 100.0% 60 100.0%  
***significant at p<0.001 level 
Table no.11shows the pretest and post-test level of knowledge score 
among caregivers Before education module, none of the caregivers are having 
good level knowledge score, 26.7% are having Moderate level knowledge 
score and 73.3% of them having poor level of knowledge score on pyramidal 
symptoms  
After education module, 38.3% of the caregivers are having good level 
knowledge score, 61.7% are having Moderate level knowledge score and none 
of them  having poor  level of knowledge score on pyramidal symptoms  
Level of knowledge score between pretest and posttest was calculated 
using Generalised McNemar’s chi square test.  
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Table 4.12: Effectiveness and generalization of psycho education module 
 
Max 
score 
Mean score 
Mean symptoms 
knowledge score 
with 95% 
Confidence interval 
Percentage  of 
symptoms 
knowledge score 
with 95% 
Confidence interval 
Pretest 66 30.15 
16.52(15.37 – 17.66) 
25.03% (23.28% –
26.75%) Posttest 66 13.63 
The above table 4.12 shows the effectiveness of psycho education 
module in knowledge regarding extra pyramidal symptoms among caregivers 
of patients on antipsychotic drugs attending outpatient department at IMH, 
Chennai 
On an average, in posttest after having psycho education module, 
caregivers are having symptom reduction knowledge score 25.03%  score than  
pretest score.  
Differences and generalization of knowledge score between pretest and posttest 
score was calculated using and mean difference with 95% CI and   proportion 
with 95% CI. 
In this study effectiveness of the study is point estimate of 25.03% and 
interval estimate is 23.28% to 26.75%. It means in this similar setup of the 
study, whom ever conducted, 95 % we can assure, effectiveness of the study 
will lies between 23.28% to 26.75%symptom knowledge score. 
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Section V: Association between posttest knowledge score and selected 
demographic variables. 
Table 4.13: Association between pretest level of symptom knowledge score 
and caregivers demographic variables. 
Demographic variables 
Pretest level of symptom  
knowledge  score 
n 
Chi square 
test Good Moderate Poor 
n % n % n % 
Age 
21 -30 years 0 0.0% 10 26.3% 28 73.7% 38 χ2=2.84 
P=0.41(NS) 31 -40 years 0 0.0% 3 23.1% 10 76.9% 13 
41 -50 years 0 0.0% 3 50.0% 3 50.0% 6 
51 -60 years 0 0.0% 0 0.0% 3 100.0% 3 
Sex 
Male 0 0.0% 13 32.5% 27 67.5% 40 χ2=2.08 
P=0.14(NS) Female 0 0.0% 3 15.0% 17 85.0% 20 
Living area 
Rural 0 0.0% 11 31.4% 24 68.6% 35 χ2=2.25 
P=0.32(NS) Urban 0 0.0% 5 25.0% 15 75.0% 20 
Semi urban 0 0.0% 0 0.0% 5 100.0% 5 
Marriage 
Married 0 0.0% 11 30.6% 25 69.4% 36 χ2=2.10 
P=0.35(NS) Unmarried 0 0.0% 5 26.3% 14 73.7% 19 
Widow 0 0.0% 0 0.0% 5 100.0% 5 
Others 0 0.0% 0 0.0% 0 0.0% 0 
Occupation 
Cooly 0 0.0% 8 26.7% 22 73.3% 30 χ2=1.21 
P=0.75(NS) Business 0 0.0% 7 31.8% 15 68.2% 22 
State 
government 
0 0.0% 1 14.3% 6 85.7% 7 
Central 
government 
0 0.0% 0 0.0% 1 100.0% 1 
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Family 
Joint family 0 0.0% 3 15.8% 16 84.2% 19 
χ2=2.60 
P=0.27(NS) 
Nuclear 
family 0 0.0% 11 35.5% 20 64.5% 31 
Extended 
family 0 0.0% 2 20.0% 8 80.0% 10 
Income of the 
family 
Rs 5001- 
10,000 0 0.0% 8 26.7% 22 73.3% 30 
χ2=0.45 
P=0.92(NS) 
Rs 10,001- 
20,000 0 0.0% 5 27.8% 13 72.2% 18 
Rs 20,001- 
30,000 0 0.0% 2 33.3% 4 66.7% 6 
>Rs 30,000 0 0.0% 1 16.7% 5 83.3% 6 
Years of 
getting 
treatment for 
psychosis 
1- 5 years 0 0.0% 7 29.2% 17 70.8% 24 
χ2=5.30 
P=0.15(NS) 
6 -10 years 0 0.0% 4 19.0% 17 81.0% 21 
11- 15 years 0 0.0% 5 50.0% 5 50.0% 10 
> 15 years 0 0.0% 0 0.0% 5 100.0% 5 
Side effects of 
antipsychotic
s are 
Drawling of 
saliva 0 0.0% 6 28.6% 15 71.4% 21 
χ2=1.75 
P=0.62(NS) 
Rigidity of 
body and 
neck 
0 0.0% 8 30.8% 18 69.2% 26 
Eye balls 
moves up 0 0.0% 1 10.0% 9 90.0% 10 
Fever with 
palpitation 0 0.0% 1 33.3% 2 66.7% 3 
EPS means 
Extra 
psychiatric 
symptoms 
0 0.0% 3 11.5% 23 88.5% 26 
χ2=6.06 
P=0.10(NS) 
Extra 
pyramidal 
symptoms 
0 0.0% 9 42.9% 12 57.1% 21 
Extra 
pyramidal 
syndrome 
0 0.0% 3 33.3% 6 66.7% 9 
Extra six 
symptoms 0 0.0% 1 25.0% 3 75.0% 4 
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Treatment 
measure for 
EPS is 
Getting 
treatment in 
psychiatric 
OPD 
0 0.0% 10 33.3% 20 66.7% 30 
χ2=2.04 
P=0.56(NS) 
Getting local 
traditional 
treatment 
0 0.0% 3 16.7% 15 83.3% 18 
Getting black 
magic 
treatment 
0 0.0% 1 16.7% 5 83.3% 6 
Stop to 
attending 
psychiatric 
OPD 
0 0.0% 2 33.3% 4 66.7% 6 
The above table 4.13 shows the association between pretest level of symptom 
knowledge and their demographic variables. None of the demographic 
variables are significantly associated with their pretest level of knowledge 
score. Statistical significance was calculated using chi square test.  
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Table 4.14: Association between posttest level of symptom knowledge score 
and caregivers demographic variables 
Demographic variables 
Posttest level of symptom 
knowledge  score 
N Chi square 
test Good Moderate Poor 
n % n % n % 
Age 21 -30 years 19 50.0% 19 50.0% 0 0.0% 38 χ2=8.10 
P=0.05*(S) 31 -40 years 5 38.5% 8 61.5% 0 0.0% 13 
41 -50 years 0 0.0% 6 100.0% 0 0.0% 6 
51 -60 years 0 0.0% 3 100.0% 0 0.0% 3 
Sex Male 21 52.5% 19 47.5% 0 0.0% 40 χ2=10.18 
P=0.01**(S) Female 2 10.0% 18 90.0% 0 0.0% 20 
Living area Rural 16 45.7% 19 54.3% 0 0.0% 35 χ2=2.25 
P=0.32(NS) Urban 5 25.0% 15 75.0% 0 0.0% 20 
Semi urban 2 40.0% 3 60.0% 0 0.0% 5 
Marriage Married 16 44.4% 20 55.6% 0 0.0% 36 χ2=2.31 
P=0.31(NS) Unmarried 5 26.3% 14 73.7% 0 0.0% 19 
Widow 2 40.0% 3 60.0% 0 0.0% 5 
Others 0 0.0% 0 0.0% 0 0.0% 0 
Occupation Cooly 10 33.3% 20 66.7% 0 0.0% 30 χ2=1.73 
P=0.42(NS) Business 10 45.5% 12 54.5% 0 0.0% 22 
State 
government 2 28.6% 5 71.4% 0 0.0% 7 
Central 
government 1 100.0% 0 0.0% 0 0.0% 1 
Family Joint family 3 15.8% 16 84.2% 0 0.0% 19 χ2=6.40 
P=0.05*(S) 
Nuclear family 16 51.6% 15 48.4% 0 0.0% 31 
Extended family 4 40.0% 6 60.0% 0 0.0% 10 
Income of 
the family 
Rs 5001- 10,000 9 30.0% 21 70.0% 0 0.0% 30 χ2=2.32 
P=0.50(NS) 
Rs 10,001- 
20,000 9 50.0% 9 50.0% 0 0.0% 18 
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Rs 20,001- 
30,000 3 50.0% 3 50.0% 0 0.0% 6 
>Rs 30,000 2 33.3% 4 66.7% 0 0.0% 6 
Years of 
getting 
treatment 
for 
psychosis 
1- 5 years 10 41.7% 14 58.3% 0 0.0% 24 χ2=10.57 
P=0.01**(S) 
6 -10 years 8 38.1% 13 61.9% 0 0.0% 21 
11- 15 years 4 40.0% 6 60.0% 0 0.0% 10 
> 15 years 1 20.0% 4 80.0% 0 0.0% 5 
Side effects 
of 
antipsychot
ics are 
Drawling of 
saliva 8 38.1% 13 61.9% 0 0.0% 21 
χ2=2.12 
P=0.54(NS) 
Rigidity of body 
and neck 12 46.2% 14 53.8% 0 0.0% 26 
Eye balls moves 
up 2 20.0% 8 80.0% 0 0.0% 10 
Fever with 
palpitation 1 33.3% 2 66.7% 0 0.0% 3 
EPS means Extra psychiatric 
symptoms 11 42.3% 15 57.7% 0 0.0% 26 
χ2=0.57 
P=0.90(NS) 
Extra pyramidal 
symptoms 8 38.1% 13 61.9% 0 0.0% 21 
Extra pyramidal 
syndrome 3 33.3% 6 66.7% 0 0.0% 9 
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Extra six 
symptoms 1 25.0% 3 75.0% 0 0.0% 4 
 Treatment 
measure 
for EPS is 
Getting 
treatment in 
psychiatric OPD 
14 46.7% 16 53.3% 0 0.0% 30 
χ2=2.32 
P=0.50(NS) 
Getting local 
traditional 
treatment 
6 33.3% 12 66.7% 0 0.0% 18 
Getting black 
magic treatment 2 33.3% 4 66.7% 0 0.0% 6 
Stop to attending 
psychiatric OPD 1 16.7% 5 83.3% 0 0.0% 6 
The above table 4.14 shows the association between posttest level of 
knowledge and caregivers demographic variables. Younger age caregivers, 
male gender caregivers, joint family caregivers, less duration of treatment  
patients caregiver are having more symptom reduction knowledge than 
others..Statistical significance was calculated using chi square test.  
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Table 4.15: Association between knowledge reduction score and 
demographic variables 
Demographic variables 
symptom reduction 
knowledge  score 
n 
Oneway ANOVA 
F-test/t-test 
Pretest Posttest 
Reduction 
score=Post-
Pre 
Mean SD Mean SD Mean SD 
Age 
21 -30 years 30.00 4.66 11.39 3.27 18.61 4.50 38 
F=2.75P=0.05*(S) 
31 -40 years 30.46 4.33 15.24 2.37 15.22 4.66 13 
41 -50 years 30.17 6.74 15.17 2.40 15.00 5.32 6 
51 -60 years 30.67 4.04 16.00 2.00 14.67 3.79 3 
Sex 
Male 30.43 4.90 13.33 2.89 17.10 4.78 40 
t=2.39P=0.05*(S) 
Female 30.60 3.91 16.40 3.08 14.20 3.59 20 
Living area 
Rural 29.23 4.82 13.03 2.86 16.20 4.59 35 
F=0.25 
P=0.77(NS) Urban 31.25 4.33 14.15 2.32 17.10 4.29 20 
Semi urban 32.20 4.21 15.80 4.82 16.40 4.39 5 
Marriage 
Married 29.39 4.78 13.61 3.24 15.78 4.84 36 
F=2.43 P=0.10(NS) 
Unmarried 30.74 4.23 13.79 2.64 16.95 3.39 19 
Widow 33.40 4.72 13.20 2.39 20.20 3.11 5 
Others 0.00 0.00 0.00 0.00 0.00 0.00 0 
Occupation 
Cooly 30.67 4.33 14.27 3.19 16.40 3.69 30 
F=0.27P=0.85(NS) 
Business 29.55 5.10 12.82 2.75 16.73 5.32 22 
State 
government 
29.86 5.55 14.00 1.83 15.86 4.98 7 
Central 
government 
30.00 0.00 10.00 0.00 20.00 0.00. 1 
Family 
Joint family 31.95 4.13 15.05 3.10 16.89 3.78 19 
F=6.40 P=0.05*(S) 
Nuclear 
family 
32.70 5.08 13.50 2.88 19.20 6.14 31 
Extended 
family 
28.23 4.13 12.81 2.64 15.42 3.85 10 
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Income of the 
family 
Rs 5001- 
10,000 
30.37 4.45 14.17 2.74 16.20 4.08 30 
F=0.89 P=0.44(NS) 
Rs 10,001- 
20,000 
28.94 4.29 13.06 3.30 15.89 3.71 18 
Rs 20,001- 
30,000 
32.00 7.24 13.00 3.95 19.00 7.24 6 
>Rs 30,000 30.83 4.26 13.33 1.86 17.50 4.97 6 
Years of 
getting 
treatment for 
psychosis 
1- 5 years 30.04 4.88 11.83 2.82 18.21 5.06 24 
F=2.75 P=0.05*(S) 
6 -10 years 31.24 4.46 13.56 3.36 17.68 3.64 21 
11- 15 years 27.30 4.69 12.80 2.74 14.50 4.79 10 
> 15 years 29.80 2.68 15.80 2.77 14.00 2.35 5 
Side effects of 
antipsychotics 
are 
Drawling of 
saliva 
30.14 3.99 13.62 3.35 16.52 3.63 21 
F=0.49 P=0.68(NS) 
Rigidity of 
body and 
neck 
30.65 5.12 13.62 2.82 17.04 4.91 26 
Eye balls 
moves up 
29.40 4.79 13.50 2.55 15.90 4.95 10 
Fever with 
palpitation 
28.33 6.66 14.33 4.04 14.00 4.36 3 
EPS means 
Extra 
psychiatric 
symptoms 
30.19 4.05 13.04 2.52 17.15 4.25 26 
F=2.57 P=0.46(NS) 
Extra 
pyramidal 
symptoms 
28.95 5.05 14.14 3.45 14.81 4.18 21 
Extra 
pyramidal 
syndrome 
30.44 5.36 13.56 2.30 16.89 4.04 9 
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Extra six 
symptoms 
29.00 5.03 15.00 4.24 14.00 4.69 4 
Treatment 
measure for 
EPS is 
Getting 
treatment in 
psychiatric 
OPD 
29.77 4.58 13.37 3.21 16.40 4.30 30 
F=2.32 P=0.50(NS) 
Getting 
local 
traditional 
treatment 
31.61 4.38 13.94 2.98 17.67 4.45 18 
Getting 
black magic 
treatment 
31.33 3.93 13.17 2.56 18.17 2.86 6 
Stop to 
attending 
psychiatric 
OPD 
28.50 5.47 14.50 2.17 14.00 4.00 6 
The above table 4.15 shows the association between symptom reduction knowledge 
score and demographic variables. Younger age caregivers,, male gender caregivers, 
joint family caregivers, less duration of treatment  patients caregiver are having more 
symptom reduction knowledge than others... Statistical significance was calculated 
using oneway analysis of variance F-test and student independent t-test.  
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CHAPTER-V 
DISCUSSION 
 The study intends to assess the effectiveness of psycho education 
module on knowledge regarding extra pyramidal symptoms among care givers 
of   patients on anti-psychotic drugs attending outpatient department at Institute 
of Mental Health , Chennai. The data was collected with the help of structured 
questionnaire .Paired ‘t’ test was used to test the significant difference between 
pre test and post test, chi-square was used to find out the association between 
knowledge with selected demographic variables. 
The collected data were tabulated and presented according to the 
objectives under the following headings 
 Section I:  
Deals with the socio demographic variables 
 Section II: 
Assess the pre test knowledge of caregiver regarding extra pyramidal 
symptoms. 
 Section III: 
Assess the post test knowledge of caregiver regarding extra pyramidal 
symptoms. 
 Section IV:  
Assess the effectiveness of psycho education module. 
 
 Section V: 
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Association between post test knowledge score and selected 
demographic variables. 
The first objective of the study to assess the socio demographic variables 
and pre test knowledge of care giver regarding extra pyramidal 
symptoms: 
• Among 60 caregivers (63.3%) were 21-30 years, (21.7%) were 
31-40 years,  (10%) were 41-50 years, (5%) were 51-60 years. 
• In case of sex (66.7%) were males, (33.3%) were females. 
• According to living area (58.3%) were from rural, (33.4%) were 
from urban, (8.3%) were from semi urban. 
• In marital status (60%) were married, (31.7%) were unmarried, 
(8.3%) were widow, and none of them in other categories. 
• According to occupation status (50%) were cooly, (36.6%) were 
doing business, (11.7%) were state government employee, (1.7%) 
were central government employee. 
• The type of family revealed that (51.7%) were nuclear family, 
(31.6%) were joint family, and (16.7%) were extended family. 
• Regarding income of the family (50%) were earned Rs. 5001-
10,000, (30%) were  earned Rs. 10,001-20,000, (10%) Rs. 
20,001-30,000, (10%) were earned more than  30,000. 
• According to years of getting treatment for psychosis (40%) were 
1-5 years, (35%)  were 6-10 years, (16.7%) were 11-15 years 
and (8.3%) were more than 15 years. 
• Knowledge regarding side effects of antipsychotics was (43.3%) 
thought rigidity of  body and neck, (35%) thought drawling of 
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saliva, (16.7%) thought eye balls move  up, (5%) thought fever 
with palpitation. 
• Caregiver knowledge about EPS means was (43.3%) were 
thought extra psychiatric symptoms, (35%) were thought extra 
pyramidal, (15%) were extra pyramidal syndrome, (6.7%) were 
thought extra six symptoms. 
• Caregiver knowledge about treatment measure for EPS is (50%) 
were thought getting treatment in psychiatric OPD, (30%) were 
thought getting local traditional treatment, (10%) getting black 
magic treatment, (10%) were thought stop to attending 
psychiatric OPD.  
The pre test level of knowledge score regarding extra pyramidal symptoms 
among caregivers of patients on antipsychotic drugs using Glasgow 
Antipsychotic Side-effect Scale (GASS). 
In general , none  of the caregivers are having good level knowledge 
score,  26.7% are having Moderate level knowledge score and 73.3% of them 
having poor level of knowledge score on pyramidal symptoms. 
The similar study conducted by Ram  prasad  Santhana krishna  
Kirgaval1*, Srinivas Revanakar2 and Chidanand Srirangapattna (2017) 
Prevalence of Extra pyramidal Side Effects in Patients on Antipsychotics Drugs 
at a Tertiary Care Center  Background: Antipsychotic drugs are associated with 
adverse effects that can lead to poor medication adherence, stigma, distress and 
impaired quality of life. Among the various side effects of anti-psychotics extra 
pyramidal symptoms constitute one of the important side effects interfering 
with the compliance of the patients towards medication. Objective: Evaluation 
of extra pyramidal side effects by AIMS in patients who are on antipsychotics. 
Results: The extra pyramidal symptoms were more commonly seen in males 
(62.85%), the age of incidence of maximum in the age group of ( 34.28%), 
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Maximum was seen among the patients on the Risperidone (45.7%), 
Involvement of the extremities was common (42.85%) and 64.28% of 
individuals had moderate severity and( 54.28%) of individuals were aware of 
the extra pyramidal symptoms which provided mild distress. Conclusion: Extra 
pyramidal symptoms are one of the commonest side effect of the antipsychotics 
interfering with compliance of the patients towards adherence to medications, 
thereby decreasing the efficacy. 
 Sheela ,Ranbhise, Ashok, Kamat ,(2014) conducted a study to assess the 
knowledge regarding adverse effects of selected antipsychotic drugs among the 
caregivers of patients receiving antipsychotic drugs  adopted  non experimental 
descriptive design with descriptive survey approach was used for the present 
study. Non Probability sampling by using convenient sampling technique was 
used to select 30 samples. Data was collected by means of a Standardized 
Structured Knowledge Questionnaire which was divided into 2 sections which 
consisted socio-demographic variables and variables to assess the knowledge 
regarding adverse effects of anti psychotic drugs. The study findings revealed 
that majority of caregivers 24 (80%) had average knowledge, 5 (16.66%) had 
good knowledge, 1 (3.33%) had poor knowledge about adverse effects of 
antipsychotic drugs. There is statistically significant association found between 
demographic variables with knowledge score regarding adverse effects of 
antipsychotic drugs at the 0.05 level of significance. 
  
  
85 
 
The second objective of the study to determine the pre test and post test 
knowledge of care giver regarding extra pyramidal symptoms. 
• The post test level of knowledge score regarding extra pyramidal 
symptoms among caregivers of patients on antipsychotic drugs Using 
Glasgow Antipsychotic Side-effect Scale (GASS). 
• In general 38.3% of the caregivers are having good level knowledge 
score,  61.7%  are having Moderate level knowledge score and  none of 
them having poor  level of knowledge score on pyramidal symptoms.  
• On an average, in pre test caregivers are having 30.15score after the 
administration of psycho education module they are having 13.63 
knowledge score. Difference is 16.51, Before education module, none of 
the caregivers are having good level knowledge score, 26.7% are having 
Moderate level knowledge score and 73.3% of them having poor level 
of knowledge score on pyramidal symptoms.  
• After education module, 38.3% of the caregivers are having good level 
knowledge score, 61.7% are having Moderate level knowledge score 
and none of them   having  poor  level of knowledge score on pyramidal 
symptoms . 
• Level of knowledge score between pre test and post test was calculated 
using Generalised Mc Nemar’s chi square test.  
• On  an  average,  in post test after having psycho education module, 
caregivers are having  gaining  knowledge score 25.03%  score than  
pretest  score.  
• Differences and generalization of knowledge score between pretest and 
post test score was calculated using and mean difference with 95% CI 
and  proportion with 95% CI. 
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• The similar study conducted by Eugenio Aguglia et al, 2007.  1, 
Elisabetta Pascolo-Fabrici 1, Francesca Bertossi1 and Mariano Bassi 
Eugenio Aguglia* 
A synergy of drug therapy and psychosocial interventions can give more 
benefits in treatment .Methods: A perspective study was conducted on 150 
patients with schizophrenia over 15 centers in Italy. The experimental group 
was treated with drug therapy, traditional psychosocial and psycho education 
for the patients and their families, while the control group received traditional 
psychosocial and drug intervention over 1 year. Results: The experimental 
group showed a significant statistical improvement (p < 0,05) in almost all the 
scales that have been assessed (BPRS, SAPS, SANS, SIMPSON-ANGUS 
SCALE, 
LANCASHIRE QL SCALE). Significant was the reduction of the 
number of hospitalizations and of days of hospital stay .Conclusion: As it is 
shown in international literature, psycho educational intervention with 
schizophrenic patients and their families can reduce the occurrence of relapse. 
The third objective of the study to find association between post test 
knowledge score and selected demographic variables. 
 The association between pre test level of symptom knowledge and their 
demographic variables.    
 None of the demographic variables are significantly associated with 
their pre test level of knowledge score. Statistical significance was calculated 
using chi square test.  
 The association between post test level of knowledge and caregivers 
demographic variables.    
 Younger age caregivers, male gender caregivers, joint family caregivers, 
less duration of treatment  patients caregiver are having more symptom 
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reduction knowledge than others..Statistical significance was calculated using 
chi square test. The similar study conducted by Sayali Devidas Dambhe, 
Muniyand i  S.Effectiveness  of Planned Teaching about Knowledge Regarding 
side Effects of Typical Antipsychotics among the Primary care givers of 
Psychiatric Patient in selected Hospital. Asian J. Nursing Education and 
Research. 2018; 8(1): 81-93.  
Objective: Assess the level of knowledge regarding side effects of typical 
antipsychotics among primary care givers of psychiatric patients. To assess the 
effectiveness of planned teaching on knowledge regarding typical 
antipsychotics among primary care givers of psychiatric patients. To find out 
the association between level of knowledge among primary care givers of 
mentally ill client with their selected demographic variables. 
Research approach: Present study was conducted on quantitative approach is 
used in this study. This approach was selected because the aim of this research 
study was to evaluate the effectiveness of planned teaching in improving the 
knowledge of primary care giver regarding side effects of typical 
antipsychotics drugs. With this approach it would be possible to describe the 
knowledge of primary care givers regarding side effects of typical 
antipsychotic drug. The quantitative approach would help the investigator to 
evaluate the effect of “Planned teaching” on the variable that is knowledge of 
the primary care givers. 
Research Design: One group pre-test post-test design has been used to fine the 
effectiveness of planned teaching about knowledge regarding side effects of 
typical antipsychotics among the primary care givers of psychiatric patient in 
selected hospital and also to determine the association between knowledge of 
primary care givers regarding side effect of typical antipsychotics with their 
selected demographic variables. A pre test was administered on day 1 by means 
of structural questionnaire depicted as Q1 and then planned teaching also 
conducted on day 1 depicted as X. A post test was conducted on day 7 using 
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the same structured questionnaire depicted as Q2. The study design depicted as 
(Q1,X ,Q2). 
Setting of the study: The study was conducted in a selected hospital. The 
rationale for selecting this setting was easy transport, familiarity with the 
setting, administrative approval, cooperation and availability of subject. 
Sample and sampling technique: In this study sample size was 40 primary care 
giver of psychiatric patient who take typical antipsychotics. Sampling refers to 
the process of selecting the portion of the population to represent the entire 
population.  
Tool: Knowledge questionnaire is used to gather information.  
Validity and reliability: Reliability of the tool is a major criterion for 
assessing the quality and accuracy. It is the degree of consistency with which it 
measures the attribute. Reliability analysis was done by KR20 formula. The 
reliability coefficient correlation for structured knowledge questionnaire was 
0.70 To obtain content validity of the tool, the prepared tool with synopsis, 
planned on side effects of typical antipsychotics, evaluator’s response sheet and 
content validity certificate were submit to 14 experts in the field of psychiatric 
nursing and psychiatry. All validated contents of the tools were received back 
from the experts with their valuable suggestion and comments.  
Pilot study: The investigator conducted the pilot study in selected hospital 
from 23th December 2016 to 30th December 2016. For the present study, the 
investigator obtained formal approval from the medical superintendent of in 
selected hospital. The investigator selected 4 samples by non-probability 
convenient sampling technique. After a brief self-introduction, the investigator 
explained the purpose of the study and obtained consent from them. Good 
rapport was established. The investigator conducted the pre-test and doubts 
were clarified. After that, planned teaching was given to the primary Finding of 
the study: The finding including of the study includes, the analysis and 
interpretation of data collected from the primary care givers in selected 
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hospital. Among the total 40 sample of primary care givers out of 14(35% )in 
29-38 years of  age ,most of samples were female 24( 60% ),12(50%) having 
secondary education, 26(65% )of subjects belonged to Hindu 
religion,21(52.5%) of sample was on private job, 22(55%) sample having 
upto10000, 22(55%) samples was from to urban area 26( 65%) were having 
length of stay of more than 2 year. The frequency and percentage distribution 
of level of knowledge among primary care givers in pre-test. Among 40 
samples the pre test score 3(7.5%) subjects were having poor knowledge (0-6) 
regarding the side effects antipsychotics, while 29(72.5%) had average 
knowledge (7-12),whereas 8(20%)subject had good knowledge (13-18)and 
none of the subjects had excellent knowledge about it. While in the post -
test,1(2.5%) of the subject had average knowledge,19(47.5%)subject had good 
knowledge and 20(50%)subject had excellent knowledge regarding the side 
effects of antipsychotics. The comparison between the mean difference in pre-
test and post test score was 8.2. The calculated‘t ' value was 13.71, whereas the 
tabulated‘t’ value was 2.02, shows that the calculate ‘t’ value was much higher 
than the tabulated 't' value. It shows that the planned teaching was effective in 
significant improving the knowledge of primary care givers of psychiatric 
patient regarding side effects of typical anti psychotics, so the null hypothesis 
H0 is rejected and the research hypothesis H1 is accepted.  
Conclusion: The analysis of the study revealed that there was a significant 
improvement in the knowledge of primary care givers. The planned teaching 
proved to be effective in improving the knowledge and attitude of the primary 
care givers of psychiatric patient in selected hospital. 
 
CHAPTER VI 
SUMMARY, RECOMMENDATION AND 
NURSING IMPLICATION OF THE STUDY 
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6.1 SUMMARY OF THE STUDY 
 The main focus of the study was to assess the effectiveness of psycho 
education module on knowledge regarding extra pyramidal symptoms among 
caregivers of patients on antipsychotic drugs. Antipsychotics induced extra 
pyramidal symptoms include a variety of movement disorders. Acute extra 
pyramidal symptoms are like acute dystonia, akathisia and Parkinsonism 
develop within hours or weeks after initiating or increasing doses of 
antipsychotics. Tardive  dyskinesia and tardive  dystonia are delayed onset 
syndromes and usually develop after a prolonged use of anti psychotics. 
 Descriptive and inferential statistics was used for comparison and 
association of    pre-test and post test values of psycho education module. 
Association was found by using chi-square test. The association between pre 
test level of symptom knowledge and  their demographic variables.    
 None of the demographic variables are significantly associated with 
their pre test level of knowledge score. Statistical significance was calculated 
using chi square test.  
 The association between post test level of knowledge and caregivers 
demographic variables.    
 Younger age caregivers, male gender caregivers, joint family caregivers, 
less duration of treatment  patients caregiver are having more symptom 
reduction knowledge than others..Statistical significance was calculated using 
chi square test.  
 The paired ‘t’ test was used to analyse the effectiveness of psycho 
education module on  knowledge of  extra pyramidal symptoms among 
caregivers of the patients taking anti psychotics. It was found that ‘t’ value was 
statistically significant at 5% level. This shows that psycho education module 
was effective. 
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 So the researcher conducted a study to assess the effectiveness of 
psycho education module to improve the knowledge of care givers of patients 
taking anti psychotics in Institute of mental health at Chennai. The data was 
collected for 4 weeks in Institute Mental Health, Chennai, from 02.01.2018 to 
29.01.2018. 
MAJOR FINDINGS OF THE STUDY  
6.1.1.    Findings of socio demographic profile of the care givers of patients 
with anti 
             psychotics. 
• Among 60 caregivers (63.3%) were 21-30 years, (21.7%) 
were 31-40 years,   (10%) were 41-50 years, (5%) were 51-60 
years. 
• In case of sex (66.7%) were males, (33.3%) were females. 
• According to living area (58.3%) were from rural, (33.4%) 
were from urban, (8.3%) were from semi urban. 
• In marital status (60%) were married, (31.7%) were 
unmarried, (8.3%) were widow, and none of them in other 
categories. 
• According to occupation status (50%) were cooly, (36.6%) 
were doing business, (11.7%) were state government 
employee, (1.7%) were central government employee. 
• The type of family revealed that (51.7%) were nuclear family, 
(31.6%) were joint family, and (16.7%) were extended family. 
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• Regarding income of the family (50%) were earned Rs. 5001-
10,000, (30%) were earned Rs. 10,001-20,000, (10%) Rs. 
20,001-30,000, (10%) were earned more than 30,000. 
• According to years of getting treatment for psychosis (40%) 
were 1-5 years, (35%) were 6-10 years, (16.7%) were 11-15 
years and (8.3%) were more than 15 years. 
• Knowledge regarding side effects of antipsychotics was 
(43.3%) thought rigidity of body and neck, (35%) thought 
drawling of saliva, (16.7%) thought eye balls moves up, (5%) 
thought fever with palpitation. 
• Caregiver knowledge about EPS means was (43.3%) were 
thought extra psychiatric symptoms, (35%) were thought 
extra pyramidal, (15%) were extra pyramidal syndrome, 
(6.7%) were thought extra six symptoms. 
• Caregiver knowledge about treatment measure for EPS is 
(50%) were thought getting  treatment in psychiatric OPD, 
(30%) were thought getting local traditional treatment, (10%) 
getting black magic treatment, (10%) were thought stop to 
attending  psychiatric OPD.  
6.1.2 Finding the pre test level of knowledge of extra pyramidal 
symptoms among caregivers of patients on antipsychotic drugs.   
In general, none of the caregivers are having good level knowledge 
score, 26.7% are having Moderate level knowledge score and 73.3% of them 
having poor level of knowledge score on pyramidal symptoms. 
6.1.3.    Finding the post test level of knowledge of extra pyramidal 
symptoms among caregivers of patients on antipsychotic drugs 
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The post test level of knowledge score regarding extra pyramidal symptoms 
among caregivers of patients on antipsychotic drugs Using Glasgow 
Antipsychotic Side-effect Scale (GASS). 
In general 38.3% of the caregivers are having good level knowledge 
score, 61.7% are having Moderate level knowledge score and none of them 
having poor level of knowledge score on extra pyramidal symptoms. 
6.1.4  Finding the effectiveness of psycho education module on knowledge 
regarding extra pyramidal symptoms among caregivers of patients on 
antipsychotic drugs 
On an average, in pre test caregivers are having 30.15score after the 
administration of psycho education module they are having 13.63 knowledge 
score .Difference is 16.51, This difference is statistically significant. Statistical 
significance was calculated by using student’s paired ‘t’test. 
 Differences and generalization of knowledge score between pretest and 
posttest  score was calculated  using and mean difference with 95% CI and   
proportion with 95% CI. 
In this study effectiveness of the study is point estimate of 25.03%  and 
interval estimate is 23.28% to 26.75%. It means in this similar setup of the 
study, whom ever conducted , 95 % we can assure , effectiveness of the study 
will lies between 23.28% to 26.75%symptom knowledge score. 
6. 1.5.    Finding of an association of knowledge of care givers with the 
selected demographic variables 
 Younger age caregivers, male gender caregivers, joint family caregivers, 
less duration of treatment  patients caregiver are having more symptom 
reduction knowledge than others..Statistical significance was calculated using 
chi square test.   
6.2   NURSING IMPLICATIONS OF THE STUDY 
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The finding of the study has implications for nursing education, nursing 
practice, nursing research and nursing administration. 
6.2.1.NURSING PRACTICE 
• Survey can be conducted to identify the risk group within the 
community. 
• Screening camps can be arranged and early detection can be done treat 
and prevent   EPS 
• The psychiatric nurse must have knowledge in teaching EPS and 
prevention methods in various aspects. 
• The psychiatric nurse can teach the other staff nurses and the nursing 
students regarding EPS 
 
 
6.2.2.     NURSING EDUCATION 
• Conferences, workshops and seminars can be held for nurses to impart 
update the Knowledge and positive attitudes towards antipsychotic 
drugs management. 
• In – service education to update their knowledge and skills in various 
health care settings should be given. 
• Nursing curriculum has to focus on enabling the nursing students to 
develop skill in identifying risk groups and prevents the side effect. 
6.2.3.     NURSING ADMINISTRATION 
• The present study is proposed to help the administrators to strategically 
plan and meet the health needs of the patients taking anti psychotics. 
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• The administrators in both private and government sectors should take 
initiative actions to update the knowledge of risk groups on 
schizophrenia. 
• The administrator can encourage the nurses for conducting research in 
various aspects of psychotrophic medications and its importance. 
•  The administrator can organize conference, workshop and seminars for 
nurses working in the psychiatric hospital. 
• The administrator should support the staffs to conduct programmes 
regarding promoting knowledge of extra pyramidal symptoms. 
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6.2.4.      NURSING RESEARCH 
• The study will be valuable reference material for further researchers. 
• This study is a preliminary set up for exploring the concepts of 
knowledge of side 
• effects of antipsychotics 
• The results of the study encourage the care givers of patients taking anti 
psychotics to adopt healthy life styles. 
6.3.    RECOMMENDATIONS 
             The study recommends the following for future research; 
• A similar study can be undertaken for a large sample in different 
settings. 
• A comparative study can be conducted among the staff nurses within the 
organisation. 
• A similar study can be conducted among caregivers at different settings. 
• A similar study to be conducted among nursing students. 
6.4       LIMITATION OF THE STUDY 
• The study was limited to the care givers of patients on anti psychotics. 
•  The study was limited to the selected hospital at Chennai. 
•  The care givers who were to participate in the study. 
• The data collection was restricted only for 4 weeks. 
•  The knowledge level was assessed based on the score obtained. 
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6.5. CONCLUSION 
 Education in evidence based care gives the opportunity to nurses to 
improve their ability to use theoretical knowledge in practice. So the nurses 
should educate the  care  givers  to understand the  side effects of extra 
pyramidal symptoms and advantages of psycho education .This chapter 
enlightens the importance of this research and reveals that the gaining of   
knowledge among  care givers of patients on anti psychotics. 
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FIG.2.2.1 MODIFIED ORLANDO THEORY OF NURSING 
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FIG.3.1 SCHEMATIC PRESENTATION OF RESEARCH MTHODOLOGY 
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Fig 4.1 Age distribution of caregivers 
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Fig 4.2    Sex distribution of caregivers 
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Fig 4.3     Living area of caregivers 
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Fig 4.4   Marital status of caregivers 
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Fig 4.5    occupational status of caregivers 
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Fig 4.6    Type of family system of caregivers 
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Fig 4.7    Monthly income of caregivers 
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Fig 4.8    Years of getting treatment for psychosis 
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Fig 4.9    Knowledge regarding side effects of antipsychotics 
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Fig 4.10    Knowledge regarding EPS means 
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Fig 4.11    Treatment measures for EPS 
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Fig 4.12 pretest level of knowledge score among caregivers 
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Fig 4.13 Post test level of knowledge score of caregivers
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Fig 14: Box Plot Compares the caregivers pretest and posttest knowledge score regarding extra 
pyramidal symptoms among caregivers of patients on antipsychotic drugs. 
 
 
  
 
Fig 4.15.   Pretest and posttest level of knowledge score among caregivers 
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Fig 4.16 Association between posttest level of knowledge score and caregivers age 
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Fig 4.17.   Association between posttest level of knowledge score and gender 
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Fig 4.18    Association between posttest level of knowledge score and type of family 
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Fig 4.19.  Association between post test level of knowledge score and years of getting treatment for psychosis 
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Fig 4.20     Association between symptom reduction knowledge score and demographic variables 
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“A STUDY TO ASSESS THE EFFECTIVENESS OF PSYCHO 
EDUCATION MODULE ON KNOWLEDGE REGARDING EXTRA 
PYRAMIDAL SYMPTOMS AMONG CAREGIVERS OF PATIENTS 
ON ANTIPSYCHOTIC DRUGS ATTENDING OUTPATIENT 
DEPARTMENT AT IMH, CHENNAI” 
PART – A -- SOCIO DEMOGRAPHIC VARIABLES 
SOCIO DEMOGRAPHIC VARIABLES 
1. Age 
a) 21 – 30  yrs 
b) 31 – 40 yrs 
c) 41 – 50 yrs 
d) 51 – 60 yrs 
2. Sex  
a) Male 
b) Female      
3. Living area   
a) Rural  
b) Urban  
c) Semi urban    
4. Marriage 
a) Married  
b) Unmarried  
c) Widow  
d) Others  
5. Occupation   
a) Cooly      
b) Business  
c) State government.    
d) Central government. 
  
  
  
5. Family  
a) Joint family 
b) Nuclear family 
c) Extended  
6. Income of the family 
a) Rs 5001- 10,000. 
b) Rs 10,001- 20,000. 
c) Rs 20,001- 30,000. 
d) Rs 30,000 above 
7. Years of getting treatmentfor psychosis 
a) 1- 5 years      
b) 6 -10 years  
c) 11- 15 years      
d) More than 15 years  
 
 
 
 
 
 
 
 
 
 
 
  
PART-II 
KNOWLEDGE PROFOMA 
8. Side effects of antipsychotics are  
a) Drawling of saliva.     
b) Rigidity of body and neck. 
c) Eye balls moves up.     
d) Fever with palpitation.  
9. EPS means  
a) Extra psychiatric symptoms.       
b) Extra pyramidal symptoms.  
c) Extra pyramidal syndrome.       
d) Extra six symptoms.  
10. Treatment measure for EPS is  
a) Getting treatment in psychiatric OPD.       
b) Getting local traditional treatment.  
c) Getting black magic treatment      
d) Stop to attending psychiatric OPD. 
 
 
ÁÉ ¿Ä ¸øÅ¢ ãÄõ ÁÉº¢¨¾× ÁÕóÐ¸¨Ç ¯ð¦¸¡ûÀÅ÷¸Ç¢¨¼§Â 
²üÀÎõ À¢ý Å¢¨Ç×¸û ÌÈ¢òÐ ¸ÅÉ¢òÐ ¦¸¡ûÀÅ÷¸Ç¢¨¼§Â «È¢× 
º¡÷ó¾ ¬ö× 
ÀÌ¾¢ -« ¾ý ÌÊ¨Á Å¢ÅÃõ 
 
1. À¡Ä¢Éõ.  
a) ¬ñ           
b)  ¦Àñ          
2. ÅÂÐ.  
a) 21 –30 ÅÂÐ          
b) 31 – 40 ÅÂÐ          
c) 41 – 50ÅÂÐ         
d) 51- 60 ÅÂÐ        
3. Å¡ØÁ¢¼õ.  
a) ¸¢Ã¡Áõ          
b) ¿¸Ãõ         
c) ¿¸Ãõ º¡÷ó¾         
4.¾¢ÕÁ½ Å¢ÅÃõ.          
a) ¾¢ÕÁ½Á¡ÉÅ÷           
b)  ¾¢ÕÁ½Á¡¸òÅ÷          
c) Å¢¾¨Å         
e)  ÁüüÅ÷ 
5. À½¢ Å¢ÅÃõ      
a) ÜÄ¢ 
b) Å¢Â¡À¡Ãõ 
c) «ÃÍ À½¢ 
d) Áò¾¢Â«ÃÍ À½¢          
6. ÌÎõÀ Å¢ÅÃõ 
a)  ¾É¢ ÌÎõÀõ           
b) ÜðÎ ÌÎõÀõ 
c) À¡ÃõÀ¡¢Â  ÌÎõÀõ  
7. Á¡¾ ÅÕÁ¡Éõ 
a) Rs.5000 -10000          
b) Rs.10001-20000          
c) Rs.20001 – 30000 
d)  Rs.30001 ìÌ §Áø  
8. ÁÉº¢¨¾×  §¿¡öìÌ º¢¸¢î¨º Ó¨È  
a) 1 -5 ÅÕ¼õ  
b) 6 -10 ÅÕ¼õ  
c) 11 -15 ÅÕ¼õ  
d) 15 ÅÕ¼í¸ÙìÌ §Áø 
ÀÌ¾¢ -¬ - §¿¡öÌÈ¢ò¾  Å¢ÅÃí¸û 
9. ÁÉº¢¨¾× ÁÕóÐ¸Ç¡ø À¢ý Å¢¨Ç×¸û  
a)  Å¡Â¢ø þÕóÐ ±îº¢ø ´ØÌ¾ø         
b) Å¢¨ÃôÀ¡É ¸ØòÐ ÁüÚõ ¯¼ø   
c) ¸ñ½¢ø À¡¨Å §Á§Ä þÕò¾ø  
d) ¸¡öîºø ÁüÚõ À¼À¼ôÒ 
10. ÁÉº¢¨¾× ÁÕóÐ¸Ç¡ø À¢ý Å¢¨Ç×¸û ( E P S)  
a) ÁÉ §¿¡ö         
b) ÁÕó¾¡ø À¢ý Å¢¨Ç×   
c) À¢ý Å¢¨Ç× «È¢ÌÈ¢¸û  
d)  À¢ý Å¢¨Ç×¸û 
11. ÁÉº¢¨¾× ÁÕóÐ¸Ç¡ø À¢ý Å¢¨Ç×¸û º¢¸¢î¨º Ó¨È 
a) ÒÈ §¿¡ÂÇ÷ º¢¸¢î¨º À¢¡¢× 
b) Å£ðÊüÌ «Õ¸¢ø º¢¸¢î¨º  
c) Á¡Â Áó¾¢Ãõ 
d) ÒÈ §¿¡ÂÇ÷ º¢¸¢î¨ºìÌ  
 
 
 
 
 
¸¢Ä¡Š§¸¡ù ÁÉº¢¨¾× ÁÕóÐ¸¨Ç ¯ð¦¸¡ûÀÅ÷¸Ç¢¨¼§Â ²üÀÎõ 
À¢ý Å¢¨Ç×¸û ÌÈ¢òÐ / ÀüÈ¢Â Å¢ÅÃõ Å¢É¡ ¾¡û 
À¢½¢Â¡Ç÷          ¿¡û  
Å¡ØÁ¢¼õ     ÅÂÐ    À¡Ä¢Éõ  
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¢Ð
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Á
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1 «Åý / «Åû À¸Ä¢ø àì¸Á¡¸  þÕôÀ÷     
2 «Åý / «Åû  ²§¾¡ §À¡ø þÕò¾ø     
3 «Åý / «Åû ¿¢üìÌõ¦À¡ØÐ ÁÂììÁ¡¸ þÕì¸¢§Èý     
4 «Åý / «Åû þÕ¾öõ À¼À¼ôÀ¡¸ õüÚõ §Å¸Á¡¸ ¯ûÇÐ     
5 «Åý / «Åû ¾¨º þÕì¸Á¡¸ þÕò¾ø     
6 «Åý / «Åû ¨¸/ ¸¡ø ¬ÎÅÐ ÐÊôÀ¾¡¸ ¯ûÇÐ      
7 «Åý / «Åû º¡¢ÅÃ ¿¼ì¸ ÓÊÂ¡Áø ¾ûÇ¡Ê þÕò¾ø      
8 «Åý /«Åû Å¡Â¢ø þÕóÐ ±îº¢ø ´ØÌ¾ø      
9 
«Åý / «Åû ¿¼ôÀÐ ±ýÀÐ þÂø¨ÀÅ¢¼ Ì¨ÈÅ¡¸§Å 
¯ûÇÐ 
    
10 «Åý / «Åû ¯¼Ä¢ø/ Ó¸ò¾¢ø Á¡ÚÀð¼ «¨º× ¯ûÇÐ     
11 «Åý / «ÅûÀ¡÷¨Å Áí¸Ä¡¸ ¯ûÇÐ     
12 «Åý / «Åû Å¡ö ¯Ä÷óÐ ¯ûÇÐ     
13 «Åý / «Åû º¢Ú ¿£÷ ¸Æ¢ôÀ¾¢ø º¢ÃÁÁ¡¸ ¯ûÇÐ     
14 «Åý / «Åû ¯¼ÄÄ¢Å¢ø Ì¨È× /Å¡ó¾¢ ÅÕõ §À¡ø ¯ûÇÐ     
15 «Åý/«Åû àì¸¾¢øþÃÅ¢ø ÀÎì¨¸Â¢ø ®ÃÁ¡¸¢Å¢Î¸¢ÈÐ     
16 
«Åý / «Åû «¾¢¸Á¡¸ ¿¡Å¢ø ÅÈðº¢ ²üÀðÎ/ º¢Ú ¿£÷ 
¦ÅÇ¢§ÂÕ¸¢ÈÐ 
    
17 «Åý / «Åû Á¡÷À¸ò¾¢ø Òñ ÁüÚõ Å£ì¸õ ²üÀðÎûÇÐ.     
18 
«Åý / «Åû Á¡÷À¸ò¾¢ø þÕóÐ ¿£÷ §À¡ýÈ ¾¢ÃÅõ 
¦ÅÇ¢§ÂÕ¸¢ÈÐ 
    
19 «Åý / «Åû ¯¼ÖÈÅ¢ø ®ÎÀ¼ÓÊÂÅ¢ø¨Ä     
20 «Åý ¬ÏÕôÒ Å¢¨ÃôÀ¡¸  ÓÊÂÅ¢ø¨Ä     
 ¸¼ó¾ 3 Á¡¾ò¾¢ø     
21 «Åû Á¡¾Å¢Äì¸¢ø Á¡üÈõ ²üÀðÎûÇÐ     
22 «Åý / «Åû ¯¼Ä¢ø ±¨¼ ÜÊÔûÇÐ     
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 ¾ü¦¸¡¨ÄìÌ ±¾¢÷ ÅÕõ ¸¡Ã½í¸û 0-15 16-19 20+ 
1 ¦¾¡¼÷óÐ ¸ñ¸¡½¢ò¾ø ¿¢¨Ä     
2 ÌÎõÀò¾¢ÉÕìÌ ¦¾¡¢Å¢ò¾ø    
3 §ÁÄ¡ÙÕìÌ ¦¾¡¢Å¢ò¾ø / ¸ÄóÐ¨ÃÂ¡¼ø    
4 ÒÈ §¿¡ÂÇ÷ º¢¸¢î¨ºìÌ À¡¢óÐ¨Ã     
5 ÁÉ §¿¡öÁÕòÐÅÕìÌ À¡¢óÐ¨Ã    
6 µôÀó¾õ - ¾ü¦¸¡¨ÄìÌ ¿¡¼¡Áø þÕò¾ø    
7 Å¢„õ/ ¾£ ¦À¡Õð¸û ¿¡¼¡Áø þÕò¾ø    
8 
¿¡¼¡Áø þÕò¾ø ÅøÖÉ÷/ ÁüüÅ÷¸ÙìÌ 
¦¾¡¢Å¢ò¾ø 
   
9 À¸ø ¦À¡ØÐ º¢¸¢î¨º À¡¢óÐ¨Ã    
10 ÁÕòÐÅ º¢¸¢î¨ºìÌ À¡¢óÐ¨Ã    
11 ¾¡É¡¸ ÁÕòÐÅ º¢¸¢î¨ºìÌ À¡¢óÐ¨Ã    
12 ÁüÈ¨Å     
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A new self-rating scale for detecting
atypical or second-generation
antipsychotic side effects
L Waddell Southern General Hospital, Glasgow, UK.
M Taylor Springpark Centre, Glasgow, UK.
Abstract
We aimed to construct and assess a new self rating scale to detect the side
effects of second generation antipsychotics. This scale was designed to
allow a timely, sensitive and reliable method of gathering information on
the number and severity of side effects an individual suffers from. The
Glasgow Antipscyhotic Side-effect Scale (GASS) was developed after
literature review, discussion with members of the mental health team and
with service user feedback. Fifty indivudals taking second generation
antipsychotics completed the GASS along with the Liverpool Univeristy
Neuroleptic Side Effect Rating Scale, and one week later completed the
GASS for a second time. Fifty comparison subjects also completed the
GASS. The GASS was shown to have good discrimatory power and construct
validity, along with good re-test reliablity, and is put forward as a short,
helpful and valid clinical tool.
Key words
neuroleptic drugs; atypical antipsychotics; antipsychotic agents/adverse
effects; drug monitoring; questionnaires
Introduction
Adherence with antipsychotic medication is perhaps the main
determinant of relapse in schizophrenia (Robinson, et al.,
2002). The tolerability or experience of side effects of a partic-
ular antipsychotic medication has been regarded as both one of
the key factors predicting continued adherence (Tacchi and
Scott, 2005; Lambert, et al., 2004) and crucially the experience
of adverse antipsychotic side effects is commonly stated by
patients as an important reason for non-adherence (Patel and
David, 2007). This highlights the importance of an open and
systematic discussion regarding medication-related side effects,
as an acknowledgement of the risks as well as benefits of a
particular treatment help to establish a collaborative approach
between clinicians and service users and contribute to a thera-
peutic rapport.
Antipsychotic side-effect rating scales have been used over
the years to help identify and quantify the various side effects
that can occur on these medications. A literature review was
undertaken to identify all currently available antipsychotic
side-effect rating scales using Medline and other Internet search
engines with various keywords including neuroleptic, side
effects, antipsychotic, rating scale and schizophrenia. Also, med-
ical, pharmacy and nursing staff were questioned about their
experience of identifying antipsychotic side effects. All nine
currently widely available antipsychotic side-effect rating scales
were identified and reviewed to identify their strengths and
weaknesses (see Table 1).
Antipsychotic side effect rating scales have been around for
a long time. They include traditional observer rated side-effect
scales such as the Simpson-Angus (Simpson and Angus, 1970)
or the Barnes Akathisia scale (Barnes, 1989). These more often
were found in research settings than routine clinical practice,
and arguably side-effect scales, focusing only on movement dis-
order or extra-pyramidal symptoms, have now become less rel-
evant as the widely used atypical or second-generation antipsy-
chotics (SGAs) have a lower incidence of extra-pyramidal side
effects (Geddes, et al., 2000).
Additionally, although observer rated scales may avoid
over-reporting bias, they can be more time consuming than
self-report scales, and less likely to identify potentially embar-
rassing concerns such as sexual dysfunction. The Liverpool
University Neuroleptic Side-Effect Rating Scale (LUNSERS)
(Day, et al., 1995) is a commonly used self-report scale, which
concentrates on one-word symptoms but again is over a decade
old. The LUNSERS also takes time to complete as it is three
pages long, and a recent audit (Negi, 2007) found that use of
the LUNSERS did not improve case-record documentation of
side effects. Finally, experience with the LUNSERS found that
patients commonly have to ask for help in understanding terms
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such as ‘chilblains’, emphasising that the use of simple plain
English is vital in self-report scales.
We aimed to devise an easy to understand self-report side-
effect scale that was brief, valid, practical and informative. It
was envisaged that a short self-report scale would facilitate fur-
ther discussion in the clinic regarding the tolerability of anti-
psychotic medication.
Method
Ethical approval for the study was granted by the local
Research and Ethics Committee.
Constructing the scale
After referring to existing scales, important antipsychotic side
effects were listed using information from the British National
Formulary (BNF 51, Joint Formulary Committee, 2005) and
the pharmaceutical industry. Consistent with the NICE guide-
lines (NICE, 2002), these side effects were then ranked in
importance by both authors in terms of medical consequences.
In addition, a focus group of patients already taking antipsy-
chotic medication ranked the list of side effects in terms of
acceptability. Twenty-two questions were arrived at, which
summarised the prioritised side effects with priority given to
long-term adverse medical consequences. These were then
grouped into medical systems (see Table 2).
The majority of side effects addressed by the new scale are
contained in LUNSERS, but the 22 questions were converted
into unambiguous plain English, The new scale, termed the
Glasgow Antipsychotic Side-effect Scale or GASS was scored
0,1,2,3 for questions 1–20, with higher scores reflecting more
frequent experience of side effects. Questions 21 and 22 scored
0 for ‘no’ and 3 for ‘yes’. Total GASS scores were arbitrarily
divided into suggested ranges for categorical severity, that is,
0–21 = absent/mild side effects; 22–42 = moderate side effects
and 43–63 = severe side effects. A separate (unscored) column
was added to allow people completing the GASS to note if the
side effect experienced was distressing.
Participants
Fifty outpatients aged 18–65 who were currently prescribed and
taking a SGA (regardless of diagnosis or other medication pre-
scribed) consented to participate. These individuals were
recruited from outpatient and clozapine clinics in the three
North Glasgow resource centres. Adherence with prescribed
medication was confirmed at interview. Fifty comparison sub-
jects within the same age range also agreed to participate after
excluding individuals on prescribed medication and those work-
ing in mental health care. These individuals were recruited by
Table 1 Existing side-effect rating scales
Scale Number
questions
Completion Advantages Disadvantages
Simpson Angus Scale (SAS)
(Simpson and Angus, 1970)
10 Clinician rated Objective rating of EPSE, quick and
easy to perform
Focus on extrapyramidal side effects
(EPSE) only
Abnormal Involuntary Movement
Scale (AIMS)(Guy, 1976)
12 Clinician rated Objectively records presence and
severity of involuntary
movements; quick to perform
Focus on abnormal movements only
Extrapyramidal Side Effect Rating
Scale (ESRS) (Chouinard, et al.,
1980)
12 Clinician rated Quick to perform, objective
documenting of EPSE
EPSE only. No differentiation
between dyskinesia and dystonia
Drug Attitude Inventory (Hogan,
et al., 1983)
30 Self rated Simple to understand questions and
true/false answers. Assesses
attitude
Not specifically aimed at detecting
antipsychotic side-effects
Side Effects Rating Scale for the
Registration of Unwanted Effects
of Psychotropics (Lingjaerde,
et al., 1987)
47 Clinician rated Covers an extensive range of side
effects from antipsychotic
medication
Requires a lengthy semi structured
interview and clinical observation
Barnes Akathisia Rating Scale
(Barnes, 1989)
4 Clinician and self rated
components
Both subjective and objective
rating of akathisia; quick
Focuses on akathisia only
Hillside Akathisia Scale (HAS)
(Fleischhaker, et al., 1989)
5 Clinician and self rated
components
Both subjective and objective
rating of akathisia; quick
Focuses on akathisia only
Liverpool University Neuroleptic
Side Effect Rating Scale
(LUNSERS)
(Day, et al., 1995)
51 Self rated Assesses wide range of side effects;
red herring questions for over-
reporting of side-effects
One-word symptoms that can be
difficult to understand
Antipsychotic Non-Neurological Side
Effect Rating Scale (ANNSERS)
(Yusufi, et al., 2005)
35 Clinician and self rated
components
Covers wide range of side effects
for 1st and 2nd generation
antipsychotics
Lengthy and time consuming
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Table 2 Glasgow Antipsychotic Side-effect Scale (GASS)
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directly approaching members of public in the streets of central
Glasgow. Individuals unable to read English were also excluded.
Assessment of the new scale
Outpatients completed both the LUNSERS and the GASS at
the same time, with the choice of which scale was completed
first being randomly assigned via coin tossing. The outpatients
were also asked to complete a copy of the GASS again a week
later to assess test–retest reliability. Comparison subjects com-
pleted the GASS to report that the GASS could differentiate
between those taking and those not taking SGAs.
Statistical analyses were performed using MedCalc for Win-
dows, version 9.2.0.1 (MedCalc Software). Categorical
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differences were determined using the Mann–Whitney test,
with significance set at P < 0.05. Level of agreement between
the scales was assessed using the weighted κ and Spearman cor-
relation coefficient.
Results
The GASS is illustrated above (see Table 2).
Table 3 shows the mean ages and the mean GASS score for
the two groups.
There was no significant difference in age between the two
groups (U = 1410, P = 0.27). The GASS scores for the two
groups differed significantly (Mann–Whitney U-test, U = 2336,
P < 0.0001) with a mean of 14.3 for those on antipsychotic
medication, and 3.6 for those not on medication. This confirms
the construct validity of the GASS.
Figure 1 shows the spread of the GASS scores within each
of the proposed categorical cut-off points, for both cases and
normal comparisons. Cases prescribed polypharmacy or mono-
therapy are also shown separately. As expected, all controls
scored within the absent to mild category.
Twenty-nine of the outpatient group were prescribed cloza-
pine, nine risperidone (seven oral, two depot), eight olanzapine
and four amisulpride. All doses were prescribed within BNF
limits. Thirty-six outpatients were prescribed only a SGAs,
whereas the remaining 14 were on other regular medications
(eight on antidepressants, five on mood stabilisers, one procy-
clidine, one methadone and one oral hypoglycaemics).
Repeating the analysis of GASS scores excluding the results
of the 14 polypharmacy outpatients still showed that outpati-
ents had a significantly higher mean GASS score of 11.5
(SD = 7.9) and they differed significantly from the normal
comparisons (U score 1681, P < 0.0001).
When the GASS was compared to the LUNSERS in the 50
outpatients, the κ score = 0.73, with Spearman rank correlation
coefficient = 0.93 (sum of squared differences = 1548). This
indicates a strong level of agreement between the GASS and
LUNSERS.
Only 17 of the 50 outpatients returned (by post) the second
GASS questionnaire adequately filled out a week later. Test–
retest reliability was good, with κ = 0.72. The Mann–Whitney
U-test failed to identify any significant difference in the GASS
score of those who returned the second GASS questionnaire
and those who did not (U = 308, P = 0.57) or in their age
(U = 284, P = 0.94). There were 10 men and seven women in
the group that returned the second GASS compared with 16
men and 17 women in the group that did not.
Discussion
We have constructed a new self-report rating scale assessing
SGA side effects that is easy to use. The GASS takes 5 min to
complete and contains self-explanatory questions in everyday
plain English while providing a structured systematic method
of reviewing antipsychotic side effects. In the waiting room of
a busy community mental health team or on the inpatient unit,
the use of simple and jargon-free language will surely enhance
understanding and accurate completion of a self-report scale,
particularly if that scale is seen as brief. Furthermore, recognis-
ing that the experience of a side effect may not necessarily be
adverse even if it is common or may not cause distress or func-
tional impairment when present, following our data collection
we added a column to the GASS allowing the subject to rate
whether the experienced side effect was in fact distressing (or
not). This was left as a simple global ‘yes/no’ response in view
of the complexity of this judgement. Thus, the GASS allows a
grading not only of the frequency of an experienced side effect
but also a subjective judgement of the distress associated with a
particular side effect.
The widespread use of SGAs along with their recommenda-
tion by influential guidelines (NICE, 2002) is in large part
because of a perception of increased tolerability, although
recent independent studies (e.g., Lieberman, et al., 2005) have
confirmed SGAs have important adverse side effects with asso-
ciated long-term health implications. Many studies have
reported that adherence with prescribed medication is a key
determinant of relapse prevention (seeTacchi and Scott,
2005), and medication side effects are commonly cited by
patients as a main reason for non-adherence (Patel and
David, 2007), perhaps because clinicians consistently underesti-
mate the severity and frequency of side effects. The routine use
of rating scales or systematised evaluation in psychiatry is not
Table 3 Mean ages and GASS scores of participants
Statistic Cases (n = 50) Comparisons (n = 50)
Mean age (years) [SD] 41.4 [9.1] 39.9 [14.1]
Age range (years) 24–65 19–65
No. males 26 21
Mean GASS [SD] 14.3 [10.5] 3.6 [4.1]
GASS, Glasgow Antipsychotic Side-effect Scale; SD, standard deviation.
Figure 1 Spread of Glasgow Antipsychotic Side-effect Scale scores.
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widespread, but arguably will increase and can be used to
enhance the clinician–patient interaction. Self-report scales
generally are less onerous for the busy clinician but also allow
more complete and considered responses as well as minimising
potential embarrassment on subjects such as sexual
dysfunction.
Older side-effect rating scales (see Table 1) such as AIMS,
Simpson Angus and Barnes Akathisia tended to focus exclu-
sively on movement disorder and extrapyramidal symptoms
and were usually observer rated. The more recent scales such
as LUNSERS and ANNSERS are more comprehensive and
suitable for SGAs but are lengthy and time consuming. The
LUNSERS is regularly used in the United Kingdom, despite
its size, age and occasionally confusing language, illustrating
that a systematic appraisal of medication side effects is consid-
ered important. Both the weighted κ score and Spearman’s
rank correlation score reported a very good level of agreement
between the LUNSERS and the GASS in a representative psy-
chiatric outpatient population. This is not surprising given that
the majority of the questions in the GASS are also covered by
the LUNSERS. The test–retest results also indicate that the
GASS is reliable and stable over time. We reported that indi-
viduals taking SGAs had significantly higher GASS scores than
matched normal comparison subjects, as hypothesised, and this
was not confounded by polypharmacy.
We believe our use of medical and consumer opinion as well
as the literature review enhances the face validity of the GASS,
and as the GASS combines brevity with validity, it is suitable
for busy clinical environments and as part of routine clinical
monitoring, for example, during ward round or outpatient
review. The GASS can also be completed outside the actual
clinical interview, and can thus open up discussion between cli-
nician and service user on medication tolerability in a system-
atic and structured manner, rather than relying on an ad hoc
approach.
Given these results, we suggest the GASS is a valid reliable
tool, which could aid systematic clinical assessment, particu-
larly in view of its brevity and user-friendly language.
Study limitations
The GASS was only assessed in outpatients taking SGAs;
hence, the results may not be applicable to those on typical or
first-generation antipsychotics or acute inpatients. It may not
be possible to generalise the results of this study beyond a white
middle-aged population in view of the age range and ethnicity
of the two study groups. The subjective rating of distress
caused by each side effect requires further study.
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